

# Wetenschappelijk overzicht IKNL 2020



---

# Wetenschappelijk overzicht IKNL 2020

Auteur  
A.M. Kuijpers-Ruurs

# Inhoudsopgave

<b>1</b>	<b>Algemeen</b>	<b>5</b>
1.1	Publicaties met impactfactor	5
1.2	Overige publicaties	8
1.3	Proefschriften en promoties	9
1.4	Boekbijdragen	9
<b>2</b>	<b>Borstkanker</b>	<b>10</b>
2.1	Publicaties met impactfactor	10
2.2	Overige publicaties	14
2.3	Proefschriften en promoties	15
<b>3</b>	<b>Bot-en wekedelentumoren</b>	<b>16</b>
3.1	Publicaties met impactfactor	16
3.2	Overige publicaties	16
<b>4</b>	<b>Darmkanker</b>	<b>17</b>
4.1	Publicaties met impactfactor	17
4.2	Proefschriften en promoties	20
<b>5</b>	<b>Gynaecologische tumoren</b>	<b>21</b>
5.1	Publicaties met impactfactor	21
<b>6</b>	<b>Hemato-oncologie</b>	<b>23</b>
6.1	Publicaties met impactfactor	23
6.2	Overige publicaties	25
6.3	Proefschriften en promoties	25
<b>7</b>	<b>Hoofdhalskanker</b>	<b>26</b>
7.1	Publicaties met impactfactor	26
7.2	Overige publicaties	27
7.3	Proefschriften en promoties	27
<b>8</b>	<b>Huidkanker</b>	<b>28</b>
8.1	Publicaties met impactfactor	28
8.2	Overige publicaties	28
<b>9</b>	<b>Longkanker</b>	<b>30</b>
9.1	Publicaties met impactfactor	30
9.2	Overige publicaties	31
<b>10</b>	<b>Neuro-endocriene tumoren</b>	<b>32</b>
10.1	Publicaties met impactfactor	32
<b>11</b>	<b>Upper GI &amp; HPB</b>	<b>33</b>
11.1	Publicaties met impactfactor	33
11.2	Overige publicaties	36
<b>21</b>	<b>Urogenitale kanker</b>	<b>37</b>
12.1	Publicaties met impactfactor	37
12.2	Overige publicaties	38
<b>B1</b>	<b>Impactfactoren tijdschriften</b>	<b>39</b>

# 1 Algemeen

## 1.1 Publicaties met impactfactor

Beijers AJ, **Bonhof CS**, **Mols F**, Ophorst J, de Vos-Geelen J, Jacobs EM, **van de Poll-Franse LV**, Vreugdenhil G. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy. *Ann Oncol*. 2020 Jan;31(1):131-136. doi: 10.1016/j.annonc.2019.09.006. Impactfactor: 18,274

**Boddaert MS**, **Pereira C**, Adema J, Vissers KC, van der Linden YM, **Raijmakers NJ**, **Fransen HP**. Inappropriate end-of-life cancer care in a generalist and specialist palliative care model: a nationwide retrospective population-based observational study. *BMJ Support Palliat Care*. 2020 Dec 22;bmjpspcare-2020-002302. doi: 10.1136/bmjpspcare-2020-002302. Online ahead of print. Impactfactor: 2,681

Buiting HM, de Bree R, **Brom L**, Mack JW, van den Brekel MW. Humour and laughing in patients with prolonged incurable cancer: an ethnographic study in a comprehensive cancer centre. *Qual Life Res*. 2020 Apr 6. doi: 10.1007/s11136-020-02490-w. [Epub ahead of print] Impactfactor: 2,773

Campschroer T, Zhu X, **Vernooij RW**, Lock T. Re: Tamsulosin as a Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Urol*. 2020 Jan 17:101097JU00000000000000755. doi: 10.1097/JU.0000000000000755. [Epub ahead of print] No abstract available. Impactfactor: 5,925

Coenen P, Zegers AD, Stapelfeldt CM, de Maaker-Berkhof M, Abma F, van der Beek AJ, Bültmann U, **Duijts SF**. Cross-cultural translation and adaptation of the Readiness for Return To Work questionnaire for Dutch cancer survivors. *Eur J Cancer Care (Engl)*. 2020 Dec 4:e13383. doi: 10.1111/ecc.13383. Online ahead of print. Impactfactor: 2,161

de Boer AG, Greidanus MA, Dewa CS, **Duijts SF**, Tamminga SJ. Introduction to special section on: current topics in cancer survivorship and work. *J Cancer Surviv*. 2020 Mar 23. doi: 10.1007/s11764-020-00868-w. [Epub ahead of print] Impactfactor: 3,296

Devji T, Carrasco-Labra A, Qasim A, Phillips M, Johnston BC, Devasenapathy N, Zeraatkar D, Bhatt M, Jin X, Brignardello-Petersen R, Urquhart O, Foroutan F, Schandelmaier S, Pardo-Hernandez H, **Vernooij RW**, Huang H, Rizwan Y, Siemieniuk R, Lytvyn L, Patrick DL, Ebrahim S, Furukawa T, Nesrallah G, Schünemann HJ, Bhandari M, Thabane L, Guyatt GH. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. *BMJ*. 2020 Jun 4;369:m1714. doi: 10.1136/bmj.m1714. Impactfactor: 30,313

**Dijxhoorn AQ**, **Brom L**, van der Linden YM, Leget C, **Raijmakers NJ**. Prevalence of burnout in healthcare professionals providing palliative care and the effect of interventions to reduce symptoms: a systematic literature review. *Palliat Med*. 2020 Oct 16:269216320956825. doi: 10.1177/0269216320956825. Online ahead of print. Impactfactor: 3,739

**Dinmohamed AG**, **Visser O**, **Verhoeven RH**, **Louwman MW**, van Nederveen FH, Willems SM, **Merkx MA**, **Lemmens VE**, Nagtegaal ID, **Siesling S**. Correction to: Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. *Erratum in: Lancet Oncol*. 2020 May 4;:. Impactfactor: 33,752

**Dinmohamed AG, Visser O, Verhoeven RH, Louwman MW**, van Nederveen FH, Willems SM, **Merkx MA, Lemmens VE**, Nagtegaal ID, **Siesling S**. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. *Lancet Oncol*. 2020 Apr 30. pii: S1470-2045(20)30265-5. doi: 10.1016/S1470-2045(20)30265-5. [Epub ahead of print] No abstract available.  
Impactfactor: 33,752

**Dinmohamed AG, Lemmens VE, de Hingh IH, Visser O**. Relative survival in early-stage cancers in the Netherlands: a population-based study. *J Hematol Oncol*. 2020 May 12;13(1):49. doi: 10.1186/s13045-020-00888-0.  
Impactfactor: 11,059

**Dinmohamed AG, Cellamare M, Visser O, de Munck L, Elferink MA**, Westenend PJ, Wesseling J, Broeders MJ, Kuipers EJ, **Merkx MA**, Nagtegaal ID, **Siesling S**. The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands. *J Hematol Oncol*. 2020 Nov 4;13(1):147. doi: 10.1186/s13045-020-00984-1.  
Impactfactor: 11.059

Ehrenstein JK, van Zon SK, **Duijts SF, van Dijk BA**, Dorland HF, Schagen SB, Bültmann U. Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study. *J Cancer Surviv*. 2020 Jan 15. doi: 10.1007/s11764-019-00839-w. [Epub ahead of print]  
Impactfactor: 3,296

Gopal DP, **de Rooij BH, Ezendam NP**, Taylor SJ. Delivering long-term cancer care in primary care. *Br J Gen Pract*. 2020 Apr 30;70(694):226-227. doi: 10.3399/bjgp20X709481. Print 2020 May. No abstract available.  
Impactfactor: 4,190

Hermans KE, van den Brandt PA, **Loef C**, Jansen RL, Schouten LJ. Alcohol consumption, cigarette smoking and Cancer of Unknown Primary (CUP) risk: results from the Netherlands Cohort Study. *Int J Cancer*. 2020 Oct 6. doi: 10.1002/ijc.33328. Online ahead of print.  
Impactfactor: 5,145

Hermans KE, van den Brandt PA, **Loef C**, Jansen RL, Schouten LJ. Anthropometry, physical activity and cancer of unknown primary (CUP) risk: Results from the Netherlands cohort study. *Cancer Epidemiol*. 2020 Oct 21;69:101836. doi: 10.1016/j.canep.2020.101836. Online ahead of print.  
Impactfactor: 2,179

Hiensch AE, Peeters PH, Jansen M, van der Wall E, Backx FJ, **Velthuis MJ**, May AM. Socio-ecological correlates of physical activity in breast and colon cancer survivors 4 years after participation in a randomized controlled exercise trial (PACT study). *PLoS One*. 2020 Apr 16;15(4):e0231663. doi: 10.1371/journal.pone.0231663. eCollection 2020.  
Impactfactor: 2,740

Klaver KM, **Duijts SF**, Geusgens CA, Aarts MJ, Ponds RW, van der Beek AJ, Schagen SB. Internet-based cognitive rehabilitation for WORKing Cancer survivors (i-WORC): study protocol of a randomized controlled trial. *Trials*. 2020 Jul 20;21(1):664. doi: 10.1186/s13063-020-04570-1.  
Impactfactor: 1,883

Kruik-Kollöffel WJ, van der Palen J, Doggen CJ, **van Maaren MC**, Kruik HJ, Heintjes EM, Movig KL, Linssen GC. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: a retrospective cohort study in linked databases. *PLoS One*. 2020 Dec 22;15(12):e0244231. doi: 10.1371/journal.pone.0244231. eCollection 2020.  
Impactfactor: 2,740

Lacouture ME, Sibaud V, Gerber PA, **van den Hurk CJ**, Fernández-Peñas P, Santini D, Jahn F, Jordan K; ESMO Guidelines Committee. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines<sup>†</sup>. *Ann Oncol*. 2020 Nov 25:S0923-7534(20)43157-6. doi: 10.1016/j.annonc.2020.11.005. Online ahead of print.  
Impactfactor: 18,274

**Lize N, Raijmakers N**, van Lieshout R, Youssef-El Soud M, van Limpt A, van der Linden M, **Beijer S**. Psychosocial consequences of a reduced ability to eat for patients with cancer and their informal caregivers: A qualitative study. *Eur J Oncol Nurs*. 2020 Sep 18;49:101838. doi: 10.1016/j.ejon.2020.101838. Online ahead of print. Impactfactor: 1,876

Middelburg JG, Middelburg RA, van Zwielen M, Mast ME, Bhawanie A, Jobsen JJ, Rozema T, Maas H, Geijssen ED, van der Leest AH, van den Bongard DH, van Loon J, Budiharto T, **Aarts MJ**, Terhaard CH, Struikmans H; LPRO (Dutch National Organization for Radiotherapy in the Elderly). Impaired Geriatric 8 Score is Associated with Worse Survival after Radiotherapy in Older Patients with Cancer. *Clin Oncol (R Coll Radiol)*. 2020 Sep 21:S0936-6555(20)30363-0. doi: 10.1016/j.clon.2020.09.002. Online ahead of print. Impactfactor: 3,113

**Mols F**, Tomalin B, Pearce A, Kaambwa B, Koczwara B. Financial toxicity and employment status in cancer survivors. A systematic literature review. *Support Care Cancer*. 2020 Aug 31. doi: 10.1007/s00520-020-05719-z. Online ahead of print. Impactfactor: 2,635

Nekhlyudov L, **Duijts SF**, Hudson SV, Jones JM, Keogh J, Love B, Lustberg M, Smith KC, Tevaarwerk A, Yu X, Feuerstein M. Addressing the needs of cancer survivors during the COVID-19 pandemic. *J Cancer Surviv*. 2020 Apr 25. doi: 10.1007/s11764-020-00884-w. [Epub ahead of print] No abstract available. Impactfactor: 3,296

Plate CM, Krenz G, Molenbuur B, Dijkers FG, Eindhoven GB, Wachters JE, **van Dijk BA**, Halmos GB. Predictors for failure of supraglottic superimposed high-frequency jet ventilation during endoscopic upper airway surgery in pediatric patients. *Paediatr Anaesth*. 2020 Sep;30(9):1041-1043. doi: 10.1111/pan.13952. Epub 2020 Jul 17. Impactfactor: 2,311

Reedijk AM, Kremer LC, **Visser O, Lemmens VE**, Pieters R, Coebergh JW, **Karim-Kos HE**. Increasing incidence of cancer and stage migration towards advanced disease in children and young adolescents in the Netherlands, 1990-2017. *Eur J Cancer*. 2020 Jun 7;134:115-126. doi: 10.1016/j.ejca.2020.04.011. Online ahead of print. Impactfactor: 7,275

Sanders R, Araujo TB, Vliegenthart R, **van Eenbergen MC**, van Weert JC, Linn AJ. Patients' convergence of mass and interpersonal communication on an online forum: hybrid methods analysis. *J Med Internet Res*. 2020 Oct 19;22(10):e18303. doi: 10.2196/18303. Impactfactor: 5,034

Silva GB, Hernandez KC, Donati A, **Hurk CJ**. Scalp cooling to prevent chemotherapy-induced alopecia. *An Bras Dermatol*. 2020 Jun 16:S0365-0596(20)30165-3. doi: 10.1016/j.abd.2020.03.005. Online ahead of print. Impactfactor: 1,121

Stegmann ME, Geerse OP, Tange D, Richel C, **Brom L**, Engelen V, **Duijts SF**. Experiences and needs of patients with incurable cancer regarding advance care planning: results from a national cross-sectional survey. *Support Care Cancer*. 2020 Jan 3. doi: 10.1007/s00520-019-05285-z. [Epub ahead of print] Impactfactor: 2,635

Thong MS, Chan RJ, **van den Hurk CJ**, Fessele K, Tan W, Poprawski D, Fernández-Ortega P, Paterson C, Fitch MI; MASCC EMA working group. Going beyond (electronic) patient-reported outcomes: harnessing the benefits of smart technology and ecological momentary assessment in cancer survivorship research. *Support Care Cancer*. 2020 Aug 25. doi: 10.1007/s00520-020-05648-x. Online ahead of print. Impactfactor: 2,635

**van de Poll-Franse LV, de Rooij BH, Horevoorts NJ, May AM, Vink GR, Koopman M, van Laarhoven HW, Besselink MG, Oerlemans S, Husson O, Beijer S, Ezendam NP, Raijmakers NJ, Wollersheim BM, Hoedjes M, Siesling S, van Eenbergen MC, Mols F.** Perceived care and well-being of patients with cancer and matched norm participants in the COVID-19 crisis: results of a survey of participants in the Dutch PROFILES Registry. *JAMA Oncol.* 2020 Nov 25. doi: 10.1001/jamaoncol.2020.6093. Online ahead of print.

Impactfactor: 24,799

van der Hout A, Jansen F, van Uden-Kraan CF, Coupé VM, Holtmaat K, Nieuwenhuijzen GA, Hardillo JA, de Jong RJ, Tiren-Verbeet NL, Sommeijer DW, de Heer K, Schaar CG, Sedee RJ, Bosscha K, van den Brekel MW, Petersen JF, Westerman M, Honings J, Takes RP, Houtenbos I, van den Broek WT, de Bree R, Jansen P, Eerenstein SE, Leemans CR, Zijlstra JM, Cuijpers P, **van de Poll-Franse LV**, Verdonck-de Leeuw IM. Cost-utility of an eHealth application 'Oncokompas' that supports cancer survivors in self-management: results of a randomised controlled trial. *J Cancer Surviv.* 2020 Jul 12. doi: 10.1007/s11764-020-00912-9. Online ahead of print.

Impactfactor: 3,296

van der Hout A, Holtmaat K, Jansen F, Lissenberg-Witte BI, van Uden-Kraan CF, Nieuwenhuijzen GA, Hardillo JA, Baatenburg de Jong RJ, Tiren-Verbeet NL, Sommeijer DW, de Heer K, Schaar CG, Sedee RJ, Bosscha K, van den Brekel MW, Petersen JF, Westerman M, Honings J, Takes RP, Houtenbos I, van den Broek WT, de Bree R, Jansen P, Eerenstein SE, Leemans CR, Zijlstra JM, Cuijpers P, **van de Poll-Franse LV**, Verdonck-de Leeuw IM. The eHealth self-management application 'Oncokompas' that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most? *Acta Oncol.* 2020 Dec 21:1-9. doi: 10.1080/0284186X.2020.1851764. Online ahead of print.

Impactfactor: 3,701

van der Meer DJ, **Karim-Kos HE, van der Mark M, Aben KK**, Bijlsma RM, Rijneveld AW, van der Graaf WT, Husson O. Incidence, survival, and mortality trends of cancers diagnosed in adolescents and young adults (15-39 years): a population-based study in the Netherlands 1990-2016. *Cancers (Basel).* 2020 Nov 18;12(11):E3421. doi: 10.3390/cancers12113421.

Impactfactor: 6,126

**van Hove JC**, Vernooij RW, Fiander M, Nieboer P, **Siesling S**, Rotter T. Effects of oncological care pathways in primary and secondary care on patient, professional and health systems outcomes: a systematic review and meta-analysis. *Syst Rev.* 2020 Oct 25;9(1):246. doi: 10.1186/s13643-020-01498-0.

Impactfactor: 2,479

**van Roij J, Zijlstra M, Ham L, Brom L, Franssen H**, Vreugdenhil A, **Raijmakers N, van de Poll-Franse LV**; eQuiPe study group (**Vink GR**). Prospective cohort study of patients with advanced cancer and their relatives on the experienced quality of care and life (eQuiPe study): a study protocol. *BMC Palliat Care.* 2020 Sep 9;19(1):139. doi: 10.1186/s12904-020-00642-w.

Impactfactor: 2,015

Vromans RD, Pauws SC, Bol N, **van de Poll-Franse LV**, Krahmer EJ. Communicating tailored risk information of cancer treatment side effects: only words or also numbers? *BMC Med Inform Decis Mak.* 2020 Oct 27;20(1):277. doi: 10.1186/s12911-020-01296-7.

Impactfactor: 2,317

Zegers AD, Coenen P, van Belzen M, Engelen V, Richel C, Dona DJ, van der Beek AJ, **Duijts SF**. Cancer survivors' experiences with conversations about work-related issues in the hospital setting. *Psychooncology.* 2020 Oct 10. doi: 10.1002/pon.5529. Online ahead of print.

Impactfactor: 3,006

## 1.2 Overige publicaties

Mollica MA, Mayer DK, Oeffinger KC, Kim Y, Buckenmaier SS, Sivaram S, Muha C, Taib NA, Andritsch E, Asuzu CC, Bochis OV, Diaz S, Trill MD, Garcia PJ, Grassi L, Uchitomi Y, Shaikh AJ, Jefford M, Lee HJ, Johansen C, Luyirika E, Maher EJ, Mallillin MMB, Maniragaba T, Mehnert-Theuerkauf A, Pramesh CS, **Siesling S**, Spira O, Sussman J, Tang L, Hai NV, Yalcin S, Jacobsen PB. Follow-Up Care for Breast and Colorectal Cancer Across the Globe: Survey Findings From 27 Countries. *JCO Glob Oncol.* 2020 Sep;6:1394-1411. doi: 10.1200/GO.20.00180.



Noteboom EA, Perfors IA, May AM, Stegmann ME, **Duijts SF**, Visserman EA, Vivian E, Richel C, van der Wall E, de Wit N, Helsper CW. GP involvement after a cancer diagnosis; patients' call to improve decision support. BJGP Open. 2020 Nov 10:bjgpopen20X101124. doi: 10.3399/bjgpopen20X101124. Online ahead of print.

Uyl-de Groot CA, **Schuurman MS**, **Huijgens PC**, **Praagman J**. Onderdiagnostiek bij kanker door COVID-19-crisis naar diagnose, leeftijd en provincie: een cruciale rol voor eerstelijnszorgverleners. TSG. 2020 Dec 11:1-8. doi: 10.1007/s12508-020-00289-1. Online ahead of print. PMID: 33324131.

**van Alphen K**, **Versluis A**, Dercksen W, de Haas H, Lugtenberg R, Tiemensma J, Kroep J, Broadbent E, Kaptein AA, **van den Hurk C**. Giving A Face to Chemotherapy-Induced Alopecia: A Feasibility Study on Drawings by Patients. Asia Pac J Oncol Nurs. 2020 Mar 30;7(2):218-224. doi: 10.4103/apjon.apjon\_8\_20. eCollection 2020 Apr-Jun.

### 1.3 Proefschriften en promoties

Reedijk AM. Progress against childhood and young adolescent cancer in the Netherlands since 1990. Utrecht: Universiteit Utrecht; 29 oktober 2020. Promotoren: LC Kremer, R Pieters, JW Coebergh. Copromotor: **HE Karim-Kos**.

**van Hoeve JC**. The added value of oncological care pathways: data supported with healthcare professionals' and patients' perspective. Enschede: Universiteit Twente; 29 oktober 2020. Promotor: **S Siesling**. Copromotoren: EA Kouwenhoven, **RH Verhoeven**. Leden: EW Hans, JT Tamsma, **MA Merckx**, BP Wijnhoven, LJ Boersma, M Verheij.

### 1.4 Boekbijdragen

Kampman E, **Beijer S**. Hoofdstuk Kanker. In: Handboek leefstijlgeneskunde: de basis voor iedere praktijk / redactie de Vries M, de Weijer T. Houten: Bohn Stafleu van Loghum, 2020.

## 2 Borstkanker

### 2.1 Publicaties met impactfactor

Boersma LJ, Verloop J, Voogd AC, Elkhuizen PH, Houben R, van Leeuwen AE, Linn S, de Munck L, Pijnappel R, Strobbe L, van Dalen T, Wesseling J, Poortmans P. Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03). *Radiother Oncol.* 2020 Feb 10;145:201-208. doi: 10.1016/j.radonc.2020.01.018. [Epub ahead of print] Impactfactor: 4,856

Claessens AK, Erdkamp FL, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, Tjan-Heijnen VC, Bos ME; Dutch Breast Cancer Research Group (BOOG). Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. *Acta Oncol.* 2020 Jun;59(6):713-722. doi: 10.1080/0284186X.2020.1731923. Epub 2020 Mar 6. Impactfactor: 3,701

Claessens AK, Timman R, Busschbach JJ, Bouma JM, Rademaker-Lakhai JM, Erdkamp FLG, Tjan-Heijnen VC, Bos ME; Dutch Breast Cancer Research Group (BOOG). The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer. *Breast Cancer Res Treat.* 2020 Feb;179(3):677-685. doi: 10.1007/s10549-019-05495-3. Impactfactor: 3,831

Coolen AM, Korte B, Tjan-Heijnen VC, Bodewes HW, Voogd AC, Duijm LE. Additional Breast Cancer Detection at Digital Screening Mammography through Quality Assurance Sessions between Technologists and Radiologists. *Radiology.* 2020 Jan 7:191388. doi: 10.1148/radiol.2019191388. [Epub ahead of print] Impactfactor: 7,931

Dackus GM, Józwiak K, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, Sonke GS, Linn SC. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. *Breast Cancer Res Treat.* 2020 Oct 28. doi: 10.1007/s10549-020-05978-8. Online ahead of print. Impactfactor: 3,831

de Boer AZ, de Glas NA, de Mheen PJ, Dekkers OM, Siesling S, de Munck L, de Ligt KM, Liefers GJ, Portielje JE, Bastiaannet E. Effect of omission of surgery on survival in patients aged 80 years and older with early-stage hormone receptor-positive breast cancer. *Br J Surg.* 2020 Apr 7. doi: 10.1002/bjs.11568. [Epub ahead of print] Impactfactor: 5,676

de Munck L, Siesling S, Fracheboud J, den Heeten GJ, Broeders MJ, de Bock GH. Impact of mammographic screening and advanced cancer definition on the percentage of advanced-stage cancers in a steady-state breast screening programme in the Netherlands. *Br J Cancer.* 2020 Jul 9. doi: 10.1038/s41416-020-0968-6. Online ahead of print. Impactfactor: 5,791

Draeger T, Voelkel V, Groothuis-Oudshoorn CGM, Lavric M, Veltman J, Dassen A, Boersma LJ, Witteveen A, Sonke GS, Koffijberg H, Siesling S. Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs. *Value Health.* 2020 Sep;23(9):1149-1156. doi: 10.1016/j.jval.2020.05.012. Epub 2020 Aug 14. Impactfactor: 4,748

Fachal L, Aschard H, Beesley J, Barnes D, Allen J, Kar S, Pooley K, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer J, Ghousaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso M, Andrulis I, Anton-Culver H, Antonenkova N, Arason A, Arndt V, Aronson K, Arun B, Auber B, Auer P, Azzollini J, Balmaña J, Barkardottir R, Barrowdale D, Beeghly-Fadiel A, Benitez J, Bermisheva M, Białkowska K, Blanco A, Blomqvist C, Blot W, Bogdanova N, Bojesen S, Bolla M, Bonanni B, Borg A, Bosse K, Brauch H, Brenner H, Briceno I, Brock I, Brooks-Wilson A, Brüning T, Burwinkel B, Buys S, Cai Q, Caldés T, Caligo M, Camp N, Campbell I, Canzian F, Carroll J, Carter B, Castela J, Chiquette J, Christiansen H, Chung W, Claes K, Clarke C; GEMO Study Collaborators; EMBRACE Collaborators, Collée J, Cornelissen S, Couch F, Cox A, Cross S, Cybulski C, Czene K, Daly M, de la Hoya M, Devilee P,

Diez O, Ding Y, Dite G, Domchek S, Dörk T, Dos-Santos-Silva I, Droit A, Dubois S, Dumont M, Duran M, Durcan L, Dwek M, Eccles D, Engel C, Eriksson M, Evans D, Fasching P, Fletcher O, Floris G, Flyger H, Foretova L, Foulkes W, Friedman E, Fritschi L, Frost D, Gabrielson M, Gago-Dominguez M, Gambino G, Ganz P, Gapstur S, Garber J, García-Sáenz J, Gaudet M, Georgoulas V, Giles G, Glendon G, Godwin A, Goldberg M, Goldgar D, González-Neira A, Tibiletti M, Greene M, Grip M, Gronwald J, Grundy A, Guénel P, Hahnen E, Haiman C, Håkansson N, Hall P, Hamann U, Harrington P, Hartikainen J, Hartman M, He W, Healey C, Heemskerk-Gerritsen B, Heyworth J, Hillemanns P, Hogervorst F, Hollestelle A, Hoening M, Hopper J, Howell A, Huang G, Hulick P, Imyanitov E; KConFab Investigators; HEBON Investigators ([Siesling S, Verloop J](#)); ABCTB Investigators, Isaacs C, Iwasaki M, Jager A, Jakimovska M, Jakubowska A, James P, Janavicius R, Jankowitz R, John E, Johnson N, Jones M, Jukkola-Vuorinen A, Jung A, Kaaks R, Kang D, Kapoor P, Karlan B, Keeman R, Kerin M, Khusnutdinova E, Kiiski J, Kirk J, Kitahara C, Ko Y, Konstantopoulou I, Kosma VM, Koutros S, Kubelka-Sabit K, Kwong A, Kyriacou K, Laitman Y, Lambrechts D, Lee E, Leslie G, Lester J, Lesueur F, Lindblom A, Lo W, Long J, Lophatananon A, Loud J, Lubiński J, MacInnis R, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez M, Matsuo K, Maurer T, Mavroudis D, Mayes R, McGuffog L, McLean C, Mebirouk N, Meindl A, Miller A, Miller N, Montagna M, Moreno F, Muir K, Mulligan A, Muñoz-Garzon V, Muranen T, Narod S, Nassir R, Nathanson K, Neuhausen S, Nevanlinna H, Neven P, Nielsen F, Nikitina-Zake L, Norman A, Offit K, Olah E, Olopade O, Olsson H, Orr N, Osorio A, Pankratz V, Papp J, Park S, Park-Simon T, Parsons M, Paul J, Pedersen I, Peissel B, Peshkin B, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prajzandanc K, Prentice R, Presneau N, Prokofyeva D, Pujana M, Pylkäs K, Radice P, Ramus S, Rantala J, Rau-Murthy R, Rennert G, Risch HA, Robson M, Romero A, Rossing M, Saloustros E, Sánchez-Herrero E, Sandler D, Santamariña M, Saunders C, Sawyer E, Scheuner M, Schmidt D, Schmutzler R, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Scott C, Scott R, Senter L, Seynaeve CM, Shah M, Sharma P, Shen C, Shu X, Singer C, Slavin T, Smichkoska S, Southey M, Spinelli J, Spurdle A, Stone J, Stoppa-Lyonnet D, Sutter C, Swerdlow A, Tamimi R, Tan Y, Tapper W, Taylor J, Teixeira M, Tengström M, Teo S, Terry M, Teulé A, Thomassen M, Thull D, Tischkowitz M, Toland A, Tollenaar R, Tomlinson I, Torres D, Torres-Mejía G, Troester M, Truong T, Tung N, Tzardi M, Ulmer H, Vachon C, van Asperen C, van der Kolk L, van Rensburg E, Vega A, Viel A, Vijai J, Vogel M, Wang Q, Wappenschmidt B, Weinberg C, Weitzel J, Wendt C, Wildiers H, Winqvist R, Wolk A, Wu A, Yannoukakos D, Zhang Y, Zheng W, Hunter D, Pharoah P, Chang-Claude J, García-Closas M, Schmidt M, Milne R, Kristensen V, French J, Edwards S, Antoniou A, Chenevix-Trench G, Simard J, Easton D, Kraft P, Dunning A. [Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes](#). *Nat Genet.* 2020 Jan;52(1):56-73. doi: 10.1038/s41588-019-0537-1. Epub 2020 Jan 7. Impactfactor: 27,605

Filipe MD, [Siesling S](#), Vriens MR, van Diest PJ, Witkamp AJ, Mureau MA. [Socioeconomic status significantly contributes to the likelihood of immediate postmastectomy breast reconstruction in the Netherlands: a nationwide study](#). *Eur J Surg Oncol.* 2020 Sep 19:S0748-7983(20)30788-5. doi: 10.1016/j.ejso.2020.09.016. Online ahead of print. Impactfactor: 3,959

Giardiello D, Kramer I, Hoening MJ, Hauptmann M, Lips EH, Sawyer E, Thompson AM, [de Munck L, Siesling S](#), Wesseling J, Steyerberg EW, Schmidt MK. [Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer](#). *NPJ Breast Cancer.* 2020 Nov 3;6(1):60. doi: 10.1038/s41523-020-00202-8. Impactfactor: 6,0

Giardiello D, Hauptmann M, Steyerberg EW, Adank MA, Akdeniz D, Blom JC, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Haeberle L, Haiman C, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Koppert LB, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Manoochehri M, Mariani L, Nevanlinna H, Oldenburg HSA, Pelders S, Pharoah PD, Shah M, [Siesling S](#), Smit VT, Southey MC, Tapper WJ, Tollenaar RA, van den Broek AJ, van Deurzen CH, van Leeuwen FE, van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hoening MJ, Schmidt MK. [Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts](#). *Breast Cancer Res Treat.* 2020 Apr 11. doi: 10.1007/s10549-020-05611-8. [Epub ahead of print] Impactfactor: 3,831

**Hendriks MP, Verbeek XA**, van Manen JG, van der Heijden SE, Go SH, Gooiker GA, **van Vegchel T, Siesling S**, Jager A. Clinical decision trees support systematic evaluation of multidisciplinary team recommendations. *Breast Cancer Res Treat.* 2020 Sep;183(2):355-363. doi: 10.1007/s10549-020-05769-1. Epub 2020 Jul 6.  
Impactfactor: 3,831

Kaidar-Person O, Poortmans P, Offersen BV, **Siesling S**, Sklair-Levy M, Meattini I, de Ruyscher D, Kühn T, Boersma LJ. Spatial location of local recurrences after mastectomy: a systematic review. *Breast Cancer Res Treat.* 2020 Jul 13. doi: 10.1007/s10549-020-05774-4. Online ahead of print.  
Impactfactor: 3,831

Kouwenberg CA, **de Ligt KM**, Kranenburg LW, Rakhorst H, de Leeuw D, **Siesling S**, Busschbach JJ, Mureau MA. Long-term health-related quality of life after four common surgical treatment options for breast cancer and the effect of complications: a retrospective patient-reported survey among 1871 patients. *Plast Reconstr Surg.* 2020 Jul;146(1):1-13. doi: 10.1097/PRS.0000000000006887.  
Impactfactor: 4,235

Kramer I, Hoening MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, Canisius S, Abu-Ful Z, Andrulis IL, Anton-Culver H, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Bremer M, Brucker SY, Burwinkel B, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL; NBCS Collaborators, Collée JM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Giles GG, Goldgar DE, González-Neira A, Haiman CA, Håkansson N, Hamann U, Hartman M, Heemskerk-Gerritsen BAM, Hollestelle A, Hopper JL, Hou MF, Howell A; ABCTB Investigators; kConFab Investigators, Ito H, Jakimovska M, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kets CM, Khusnutdinova E, Ko YD, Kristensen VN, Kurian AW, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubiński J, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, Mavroudis D, Meindl A, Milne RL, Mulligan AM, Muranen TA, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Park-Simon TW, Peto J, Petridis C, Plaseska-Karanfilska D, Presneau N, Pyrkäs K, Radice P, Rennert G, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, See MH, Shah M, Shen CY, Shu XO, **Siesling S**, Slager S, Sohn C, Southey MC, Spinelli JJ, Stone J, Tapper WJ, Tengström M, Teo SH, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Vachon CM, van Ongeval C, van Veen EM, Winqvist R, Wolk A, Zheng W, Ziogas A, Easton DF, Hall P, Schmidt MK. *Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.* *Am J Hum Genet.* 2020 Sep 28:S0002-9297(20)30321-9. doi: 10.1016/j.ajhg.2020.09.001. Online ahead of print.  
Impactfactor: 10,502

Lameijer JR, **Voogd AC**, Pijnappel RM, Setz-Pels W, Broeders MJ, Tjan-Heijnen VC, Duijm LE. Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: an observational follow-up study from the Netherlands. *Br J Cancer.* 2020 May 11. doi: 10.1038/s41416-020-0870-2. Online ahead of print.  
Impactfactor: 5,791

Lameijer JR, Nederend J, **Voogd AC**, Tjan-Heijnen VC, Duijm LE. Frequency and diagnostic outcome of bilateral recall at screening mammography. *Int J Cancer.* 2020 Jul 4. doi: 10.1002/ijc.33187. Online ahead of print.  
Impactfactor: 5,145

Luiten JD, **Voogd AC**, Luiten EJ, Broeders MJ, Roes KC, Tjan-Heijnen VC, Duijm LE. Recall and Outcome of Screen-detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program. *Radiology.* 2020 Jan 28:191266. doi: 10.1148/radiol.2020191266. [Epub ahead of print]  
Impactfactor: 7,931

**Luyendijk M, Vernooij RW**, Blommestein HM, **Siesling S**, Uyl-de Groot CA. Assessment of studies evaluating incremental costs, effectiveness, or cost-effectiveness of systemic therapies in breast cancer based on claims data: a systematic review. *Value Health.* 2020 Nov;23(11):1497-1508. doi: 10.1016/j.jval.2020.05.008. Epub 2020 Sep 10.  
Impactfactor: 4,748

Muratov S, Canelo-Aybar C, Tarride JE, Alonso-Coello P, Dimitrova N, Borisch B, Castells X, Duffy SW, Fitzpatrick P, Follmann M, Giordano L, Hofvind S, Lebeau A, Quinn C, Torresin A, Vialli C, **Siesling S**, Ponti A, Giorgi Rossi P, Schünemann H, Nyström L, Broeders M; ECIBC contributor group. Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators. *BMC Cancer*. 2020 Aug 24;20(1):795. doi: 10.1186/s12885-020-07289-z. Impactfactor: 3,15

Simons JM, Koppert LB, Luiten EJ, van der Pol CC, Samiei S, de Wilt JH, **Siesling S**, Smidt ML. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. *Breast Cancer Res Treat*. 2020 Mar 16. doi: 10.1007/s10549-020-05589-3. [Epub ahead of print] Impactfactor: 3,831

Steenbruggen TG, van Werkhoven E, van Ramshorst MS, Dezentjé VO, Kok M, Linn SC, **Siesling S**, Sonke GS. Adjuvant chemotherapy in small node-negative triple-negative breast cancer. *Eur J Cancer*. 2020 Jun 14;135:66-74. doi: 10.1016/j.ejca.2020.04.033. Online ahead of print. Impactfactor: 7,275

van Bommel AC, **de Ligt KM**, **Schreuder K**, Maduro JH, Van Dalen T, Peeters MT, Mureau MA, **Siesling S**; NABON Breast Cancer Audit Working Group. The added value of immediate breast reconstruction to health-related quality of life of breast cancer patients. *Eur J Surg Oncol*. 2020 Jun 11:S0748-7983(20)30530-8. doi: 10.1016/j.ejso.2020.06.009. Online ahead of print. Impactfactor: 3,959

**van der Meer DJ**, Kramer I, **van Maaren MC**, van Diest PJ, Linn S, Maduro JH, Strobbe L, **Siesling S**, Schmidt MK, **Voogd AC**. Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989-2017. *Int J Cancer*. 2020 Nov 30. doi: 10.1002/ijc.33417. Online ahead of print. Impactfactor: 5,145

van Hellemond IE, Smorenburg CH, Peer PG, **Swinkels AC**, Seynaeve CM, van der Sangen MJ, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FL, van den Berkmoortel FW, de Roos WK, Linn SC, Imholz AL, de Boer M, Tjan-Heijnen VC; Dutch Breast Cancer Research Group (BOOG). Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. *Breast Cancer Res Treat*. 2020 Mar 2. doi: 10.1007/s10549-020-05567-9. [Epub ahead of print] Impactfactor: 3,831

van Nijnatten TJ, van Tiel LP, **Voogd AC**, Groothuis-Oudshoorn CG, **Siesling S**, Lobbes MB. The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study. *Breast Cancer Res Treat*. 2020 Sep 15. doi: 10.1007/s10549-020-05906-w. Online ahead of print. Impactfactor: 3,831

van Steenhoven JE, den Dekker BM, Kuijer A, van Diest PJ, Nieboer P, Zuetenhorst JM, Imholz AL, **Siesling S**, van Dalen T. Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict. *Breast Cancer Res Treat*. 2020 May 19. doi: 10.1007/s10549-020-05683-6. Online ahead of print. Impactfactor: 3,831

van Steenhoven JE, Kuijer A, **van Maaren MC**, Roos M, Elias SG, van Diest PJ, **Siesling S**, Smidt ML, Boersma LJ, van Dalen T. Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients. *Ann Surg Oncol*. 2020 Mar 20. doi: 10.1245/s10434-020-08356-2. [Epub ahead of print] Impactfactor: 4,061

van Uden DJ, Prins MW, **Siesling S**, de Wilt JH, Blanken-Peeters CF, Aarntzen EH. [18F]FDG PET/CT in the staging of inflammatory breast cancer: a systematic review. *Crit Rev Oncol Hematol*. 2020 Jul;151:102943. doi: 10.1016/j.critrevonc.2020.102943. Epub 2020 May 7. Impactfactor: 5,833

van Uden DJ, **van Maaren MC**, Strobbe LJ, Bult P, Stam MR, van der Hoeven JJ, **Siesling S**, de Wilt JH, Blanken-Peeters CF. Better survival after surgery of the primary tumor in stage IV inflammatory breast cancer. *Surgical oncology* 2020 33 (43-50).  
Impactfactor: 2,521

Vane ML, Moosdorff M, **van Maaren MC**, van Kuijk SM, van Nijnatten TJ, van Roozendaal LM, Boerma EG, de Wilt JH, Smidt ML Conditional regional recurrence risk: the effect of event-free years in different subtypes of breast cancer. *Eur J Surg Oncol*. 2020 Nov 27:S0748-7983(20)31018-0. doi: 10.1016/j.ejso.2020.11.122. Online ahead of print.  
Impactfactor: 3,959

Verhoeven D, Allemani C, Kaufman C, Mansel R, **Siesling S**, Anderson B. Breast Cancer: global quality care optimizing care delivery with existing financial and personnel resources. *ESMO Open*. 2020 Sep;4(Suppl 2):e000861. doi: 10.1136/esmoopen-2020-000861.  
Impactfactor: 5,329

Vos EL, Lingsma HF, Jager A, **Schreuder K**, Spronk P, Vrancken Peeters MT, **Siesling S**, Koppert LB. Effect of Case-Mix and Random Variation on Breast Cancer Care Quality Indicators and Their Rankability. *Value Health*. 2020 Sep;23(9):1191-1199. doi: 10.1016/j.jval.2019.12.014. Epub 2020 Aug 18.  
Impactfactor: 4,748

Vos EL, Koppert LB, Jager A, Vrancken Peeters MT, **Siesling S**, Lingsma HF. From Multiple Quality Indicators of Breast Cancer Care Toward Hospital Variation of a Summary Measure. *Value Health*. 2020 Sep;23(9):1200-1209. doi: 10.1016/j.jval.2020.05.011. Epub 2020 Aug 15.  
Impactfactor: 4,748

Walstra CJ, Schipper RJ, Winter-Warnars GA, Loo CE, **Voogd AC**, Vrancken Peeters MT, Nieuwenhuijzen GA, Beets-Tan RG. Local staging of ipsilateral breast tumor recurrence: mammography, ultrasound, or MRI? *Breast Cancer Res Treat*. 2020 Aug 8. doi: 10.1007/s10549-020-05850-9. Online ahead of print.  
Impactfactor: 3,831

Walstra CJ, Schipper RJ, Poodt IG, Maaskant-Braat AJ, Luiten EJ, Vrancken Peeters MT, Smidt ML, Degreef E, **Voogd AC**, Nieuwenhuijzen GA. Multifocality in ipsilateral breast tumor recurrence - A study in ablative specimens. *Eur J Surg Oncol*. 2020 Apr 23:S0748-7983(20)30432-7. doi: 10.1016/j.ejso.2020.04.035. Online ahead of print.  
Impactfactor: 3,959

Witteveen A, **de Munck L**, Groothuis-Oudshoorn CG, Sonke GS, Poortmans PM, Boersma LJ, Smidt ML, Vliegen IM, IJzerman MJ, **Siesling S**. Evaluating the Age-Based Recommendations for Long-Term Follow-Up in Breast Cancer. *Oncologist*. 2020 Jun 8. doi: 10.1634/theoncologist.2019-0973. Online ahead of print.  
Impactfactor: 5,025

## 2.2 Overige publicaties

Beek MA, Gobardhan PD, Klompenhouwer EG, Rutten HJ, **Voogd AC**, Luiten EJ. Ervaring met axillary reverse mapping. *Ned Tijdsch Geneesk*. 2020;164:D4222.

**Ebben KC**, **Sieswerda MS**, Luiten EJ, Heijns JB, van der Pol CC, Bessems M, Honkoop AH, Hendriks MP, **Verloop J**, **Verbeek XA**. Impact on Quality of Documentation and Workload of the Introduction of a National Information Standard for Tumor Board Reporting. *JCO Clin Cancer Inform*. 2020 Apr;4:346-356. doi: 10.1200/CCI.19.00050.

**Jansen T**, **Geleijnse G**, **van Maaren M**, **Hendriks MP**, Ten Teije A, **Moncada-Torres A**. Machine Learning Explainability in Breast Cancer Survival. *Stud Health Technol Inform*. 2020 Jun 16;270:307-311. doi: 10.3233/SHTI200172.

Meurs CJ, Menke-Pluijmers MB, **Siesling S**, Westenend PJ. RE: Long-term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ. *JNCI Cancer Spectr*. 2020 Sep 3;4(6):pkaa079. doi: 10.1093/jncics/pkaa079. eCollection 2020 Dec.

## 2.3 Proefschriften en promoties

**Atema V.** Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms. Amsterdam: Universiteit Amsterdam; 15 april 2020. Promotoren: NK Aaronson, MS Hunter.

**de Munck L.** Breast cancer screening, stage and outcome: studies based on the Netherlands Cancer Registry. Groningen: Rijksuniversiteit Groningen; 30 november 2020. Promotoren: GH de Bock, **S Siesling**.

Luiten JD. Trends in diagnostic confirmation and treatment of pre-malignant abnormalities at screening mammography. Maastricht: Universiteit Maastricht; 18 december 2020. Promotor: VC Tjan-Heijnen. Co-promotoren: LE Duijm, **AC Voogd**.

## 3 Bot-en wekedelentumoren

### 3.1 Publicaties met impactfactor

Soomers VL, Husson O, Desar IM, van de Sande MA, de Haan JJ, Verhoef C, Vriens IJ, van Houdt WJ, [van de Poll-Franse LV](#), van der Graaf WT. Patient and diagnostic intervals of survivors of sarcoma: results from the SURVSARC study. *Cancer*. 2020 Oct 1. doi: 10.1002/cncr.33181. Online ahead of print. Impactfactor: 5,772

Soomers V, Desar IM, [van de Poll-Franse LV](#), Husson O, van der Graaf WT. Quality of life and experiences of sarcoma trajectories (the QUEST study): protocol for an international observational cohort study on diagnostic pathways of sarcoma patients. *BMJ Open*. 2020 Oct 26;10(10):e039309. doi: 10.1136/bmjopen-2020-039309. Impactfactor: 2,496

Soomers VL, Desar IM, [van de Poll-Franse LV](#), van de Sande MA, de Haan JJ, Verhoef C, Vriens IJ, van Houdt WJ, Bonenkamp JJ, van der Graaf WT, Husson O. The perceived impact of length of the diagnostic pathway is associated with Health-Related Quality of Life of sarcoma survivors: results from the Dutch Nationwide SURVSARC Study. *Cancers (Basel)*. 2020 Jul 28;12(8):E2088. doi: 10.3390/cancers12082088. Impactfactor: 6,126

Weidema ME, Husson O, van der Graaf WT, Leonard H, [de Rooij BH](#), Hartle DeYoung L, Desar IM, [van de Poll-Franse LV](#). Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy. *Acta Oncol*. 2020 Aug;59(8):975-982. doi: 10.1080/0284186X.2020.1766696. Epub 2020 Jun 1. Impactfactor: 3,701

### 3.2 Overige publicaties

Lansu J, van Houdt WJ, Schaapveld M, Walraven I, van de Sande MA, [Ho VK](#), Haas RL. Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: a population-based study. *Sarcoma*. 2020 Sep 22;2020:2437850. doi: 10.1155/2020/2437850. eCollection 2020.

Timbergen MJM, van der Graaf WTA, Grünhagen DJ, Younger E, Sleijfer S, Dunlop A, Dean L, Verhoef C, [van de Poll-Franse LV](#), Husson O. Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries. *Sarcoma*. 2020 Jul 26;2020:2141939. doi: 10.1155/2020/2141939. eCollection 2020.



## 4 Darmkanker

### 4.1 Publicaties met impactfactor

Bakkers C, van der Meer R, Roumen RM, Lurvink RJ, **Lemmens VE, van Erning FN**, de Hingh IH. Incidence, risk factors, treatment, and survival of ovarian metastases of colorectal origin: a Dutch population-based study. *Int J Colorectal Dis.* 2020 Mar 10. doi: 10.1007/s00384-020-03555-5. [Epub ahead of print]  
Impactfactor: 2,108

Bakkers C, **van Erning FN**, Rovers KP, Nienhuijs SW, Burger JW, **Lemmens VE**, Aalbers AG, Kok NF, Boerma D, Brandt AR, Hemmer PH, van Grevenstein WM, de Reuver PR, Tanis PJ, Tuynman JB, de Hingh IH. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. *Eur J Surg Oncol.* 2020 Apr 18. pii: S0748-7983(20)30415-7. doi: 10.1016/j.ejso.2020.04.018. [Epub ahead of print]  
Impactfactor: 3,959

**Bonhof CS**, Trompetter HR, Vreugdenhil G, **van de Poll-Franse LV, Mols F**. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry. *Support Care Cancer.* 2020 Apr 12. doi: 10.1007/s00520-020-05438-5. [Epub ahead of print]  
Impactfactor: 2,635

**Bonhof CS, van de Poll-Franse LV**, Wasowicz DK, Beerepoot LV, Vreugdenhil G, **Mols F**. The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. *J Cancer Surviv.* 2020 Nov 13. doi: 10.1007/s11764-020-00923-6. Online ahead of print.  
Impactfactor: 3,296

**Clouth FJ, Moncada-Torres A, Geleijnse G, Mols F, van Erning FN**, de Hingh IH, Pauws SC, **van de Poll-Franse LV**, Vermunt JK. Heterogeneity in quality of life of long-term colon cancer survivors: a latent class analysis of the population-based PROFILES registry. *Oncologist.* 2020 Dec 23. doi: 10.1002/onco.13655. Online ahead of print.  
Impactfactor: 5,025

de Boer NL, Rovers K, Burger JW, Madsen EV, Brandt-Kerkhof AR, Kok NF, de Wilt JH, de Reuver PH, **Bos AC**, de Hingh IH, Verhoef C. A population-based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer. *Cancer Med.* 2020 Jul 2. doi: 10.1002/cam4.3243. Online ahead of print.  
Impactfactor: 3,491

de Voer RM, Diets IJ, van der Post RS, Weren RD, Kamping EJ, de Bitter TJJ, Elze L, **Verhoeven RH**, Vink-Börger E, Eijkelenboom A, Mensenkamp A, Nagtegaal ID, Jongmans MC, Ligtenberg ML. Clinical, pathology, genetic, and molecular features of colorectal tumors in adolescents and adults 25 Years or younger. *Clin Gastroenterol Hepatol.* 2020 Jun 22:S1542-3565(20)30845-4. doi: 10.1016/j.cgh.2020.06.034. Online ahead of print.  
Impactfactor: 8,549

Detering R, van Oostendorp SE, Meyer VM, van Dieren S, **Bos AC**, Dekker JW, Reerink O, van Waesberghe JH, Marijnen CA, Moons LM, Beets-Tan RG, Hompes R, van Westreenen HL, Tanis PJ, Tuynman JB; Dutch ColoRectal Audit Group\*. MRI cT1-2 rectal cancer staging accuracy: a population-based study. *Br J Surg.* 2020 Apr 16. doi: 10.1002/bjs.11590. [Epub ahead of print]  
Impactfactor: 5,676

Hamers PA, **Elferink MA**, Stellato RK, Punt CJ, May AM, Koopman M, **Vink GR**. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. *Int J Cancer.* 2020 Jul 7. doi: 10.1002/ijc.33200. Online ahead of print.  
Impactfactor: 5,145

Jongeneel G, Greuter MJ, **van Erning FN**, Koopman M, **Vink GR**, Punt CJ, Coupé VM. Model-based evaluation of the cost effectiveness of 3 versus 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients. *Therap Adv Gastroenterol*. 2020 Sep 16;13:1756284820954114. doi: 10.1177/1756284820954114. eCollection 2020.  
Impactfactor: 3,520

Jongeneel G, Greuter MJ, **van Erning FN**, Koopman M, Medema JP, Kandimalla R, Goel A, Bujanda L, Meijer GA, Fijneman RJ, van Oijen MG, Ijzermans J, Punt CJ, **Vink GR**, Coupé VM. Modeling Personalized Adjuvant Treatment in Early stage colon cancer (PATTERN). *Eur J Health Econ*. 2020 Sep;21(7):1059-1073. doi: 10.1007/s10198-020-01199-4. Epub 2020 May 26.  
Impactfactor: 2,367

**Keikes L**, Koopman M, Stuijver MM, **Lemmens VE**, **van Oijen MG**, Punt CJ. Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. *Acta Oncol*. 2020 Feb 12:1-9. doi: 10.1080/0284186X.2020.1722320. [Epub ahead of print]  
Impactfactor: 3,701

**Keikes L**, Koopman M, **Lemmens VE**, **van Oijen MG**, Punt CJ. Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: a population-based study. *Anticancer Res*. 2020 Aug;40(8):4331-4341. doi: 10.21873/anticancer.14436.  
Impactfactor: 1,994

Kenkhuysen MF, van der Linden BW, Breedveld-Peters JJ, Koole JL, van Roekel EH, Breukink SO, **Mols F**, Weijenberg MP, Bours MJ. Associations of the dietary World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations with patient-reported outcomes in colorectal cancer survivors 2-10 years post-diagnosis: a cross-sectional analysis. *Br J Nutr*. 2020 Oct 22:1-13. doi: 10.1017/S0007114520003487. Online ahead of print.  
Impactfactor: 3,334

Koëter T, **Elferink MA**, **Verhoeven RH**, Zimmerman DD, Wasowicz DK, Verheij M, de Wilt JH. Hospital variance in neoadjuvant rectal cancer treatment and the influence of a national guideline update: results of a nationwide population-based study. *Radiother Oncol*. 2020 Jan 30;145:162-171. doi: 10.1016/j.radonc.2019.12.020. [Epub ahead of print]  
Impactfactor: 4,856

Lurvink RJ, Bakkers C, Rijken A, **van Erning FN**, Nienhuijs SW, Burger JW, Creemers GJ, Verhoef C, **Lemmens VE**, de Hingh IH. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study. *Eur J Surg Oncol*. 2020 Nov 26:S0748-7983(20)31031-3. doi: 10.1016/j.ejso.2020.11.135. Online ahead of print.  
Impactfactor: 3,959

Nanou A, **Mol L**, Coumans FA, Koopman M, Punt CJA, Terstappen LW. Endothelium-derived extracellular vesicles associate with poor prognosis in metastatic colorectal cancer. *Cells*. 2020 Dec 15;9(12):2688. doi: 10.3390/cells9122688.  
Impactfactor: 4,829

Qaderi SM, Dickman PW, de Wilt JH, **Verhoeven RH**. Conditional survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study. *J Natl Compr Canc Netw*. 2020 Sep;18(9):1230-1237. doi: 10.6004/jnccn.2020.7568.  
Impactfactor: 9,316

Révész D, van Kuijk SM, **Mols F**, van Duijnhoven FJ, Winkels RM, Hoofs H, Kant IJ, Smits LJ, Breukink SO, **van de Poll-Franse LV**, Kampman E, **Beijer S**, Weijenberg MP, Bours MJ. Development and internal validation of prediction models for colorectal cancer survivors to estimate the 1-year risk of low health-related quality of life in multiple domains. *BMC Med Inform Decis Mak*. 2020 Mar 12;20(1):54. doi: 10.1186/s12911-020-1064-9.  
Impactfactor: 2,317

Rovers KP, Bakkers C, **van Erning FN**, Burger JW, Nienhuijs SW, Simkens GA, Creemers GM, Hemmer PH, Punt CJ, **Lemmens VE**, Tanis PJ, **de Hingh IH**. Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. *JAMA Oncol.* 2020 Jul 16:e202701. doi: 10.1001/jamaoncol.2020.2701. Online ahead of print. Impactfactor: 24,799

Staal DP, **Vlooswijk C**, **Mols F**, Lidington E, van der Graaf WT, Bijlsma RM, Husson O. Diagnosed with a common cancer at an unusual age: causal attributions of survivors of adolescent and young adult colorectal cancer. *Support Care Cancer.* 2020 May 6. doi: 10.1007/s00520-020-05502-0. [Epub ahead of print] Impactfactor: 2,635

Strous MTA, Daniels AM, Zimmermann FM, **van Erning FN**, Gidron Y, Vogelaar FJ. Is pre-operative heart rate variability a prognostic indicator for overall survival and cancer recurrence in patients with primary colorectal cancer? *PLoS One.* 2020 Aug 20;15(8):e0237244. doi: 10.1371/journal.pone.0237244. eCollection 2020. Impactfactor: 2,740

Toes-Zoutendijk E, Kooyker AI, Dekker E, Spaander MC, Opstal-van Winden AW, Ramakers C, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, Velthuysen MF, Thomeer MG, van Veldhuizen H, van Ballegooijen M, Nagtegaal ID, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I; Dutch National Colorectal Cancer Screening Working Group (**Vink GR**, **Elferink MA**). Incidence of interval colorectal cancer after negative results from first-round fecal immunochemical screening tests, by cutoff value and participant sex and age. *Clin Gastroenterol Hepatol.* 2020 Jun;18(7):1493-1500. doi: 10.1016/j.cgh.2019.08.021. Epub 2019 Aug 20. PMID: 31442598. Impactfactor: 8,549

van Baar H, Winkels RM, Brouwer JG, Posthuma L, Bours MJ, Weijenberg MP, Boshuizen HC, van Zutphen M, van Duijnhoven FJ, Kok DE, Wesselink E, Slooter GD, Spillenaar Bilgen EJ, Hansson BM, de Wilt JH, Kampman E, **Beijer S**. Associations of abdominal skeletal muscle mass, fat mass, and mortality among men and women with stage I-III colorectal cancer. *Cancer Epidemiol Biomarkers Prev.* 2020 May;29(5):956-965. doi: 10.1158/1055-9965.EPI-19-1134. Epub 2020 Mar 4. Impactfactor: 4,344

van Baar H, Bours MJ, **Beijer S**, van Zutphen M, van Duijnhoven FJ, Kok DE, Wesselink E, de Wilt JH, Kampman E, Winkels RM. Body composition and its association with fatigue in the first 2 years after colorectal cancer diagnosis. *J Cancer Surviv.* 2020 Oct 17. doi: 10.1007/s11764-020-00953-0. Online ahead of print. Impactfactor: 3,296

van den Berg I, van de Weerd S, Roodhart JM, **Vink GR**, van den Braak RR, Jimenez CR, Elias SG, van Vliet D, Koelink M, Hong E, van Grevenstein WM, van Oijen MG, Beets-Tan RG, van Krieken JH, IJzermans JN, Medema JP, Koopman M; CONNECTION-study group. Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study. *BMC Cancer.* 2020 Aug 18;20(1):776. doi: 10.1186/s12885-020-07236-y. Impactfactor: 3,15

van 't Erve I, Greuter MJ, Bolhuis K, Vessies DC, Leal A, **Vink GR**, van den Broek D, Velculescu VE, Punt CJ, Meijer GA, Coupé VM, Fijneman RJ. Diagnostic strategies towards clinical implementation of liquid biopsy RAS/BRAF circulating tumor DNA analyses in patients with metastatic colorectal cancer. *J Mol Diagn.* 2020 Sep 19:S1525-1578(20)30462-1. doi: 10.1016/j.jmoldx.2020.09.002. Online ahead of print. Impactfactor: 5,553

Vessies DC, Greuter MJ, van Rooijen KL, Linders TC, Lanfermeijer M, Ramkisoensing KL, Meijer GA, Koopman M, Coupé VM, **Vink GR**, Fijneman RJ, van den Broek D. Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing. *Sci Rep.* 2020 May 15;10(1):8122. doi: 10.1038/s41598-020-64822-7. Impactfactor: 3,998

Wensink GE, **Elferink MA**, May AM, **Mol L**, Hamers PA, Bakker SD, Creemers GJ, de Groot JW, de Klerk GJ, Haberkorn BC, Haringhuizen AW, Hoekstra R, Hunting JC, Kerver ED, Mathijssen-van Stein D, Polée MB, Pruijt JF, Quarles van Ufford-Mannesse P, Radema S, Rietbroek RC, Simkens LH, Tanis BC, Ten Bokkel Huinink D, Tjin-A-Ton ML, Tromp-van Driel CS, Troost MM, van de Wouw AJ, van den Berkmortel FW, van der Pas AJ, van der Velden AM, van Dijk MA, van Dodewaard-de Jong JM, van Druten EB, van Voorthuizen T, Jan Veldhuis G, Verheul HM, Vestjens HJ, Vincent J, Kranenburg OW, Punt CJ, **Vink GR**, Roodhart JM, Koopman M. *Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era*. Br J Cancer. 2020 Oct 13. doi: 10.1038/s41416-020-01076-0. Online ahead of print.

Impactfactor: 5,791

Wesselink E, van Baar H, van Zutphen M, Tibosch M, Kouwenhoven EA, Keulen ET, E Kok D, van Halteren HK, Breukink SO, de Wilt JH, Weijenberg MP, Kenkhuis MF, Balvers MG, Witkamp RF, van Duijnhoven FJ, Kampman E, **Beijer S**, Bours MJ, Winkels RM. *Inflammation Is a Mediating Factor in the Association between Lifestyle and Fatigue in Colorectal Cancer Patients*. Cancers (Basel). 2020 Dec 9;12(12):E3701. doi: 10.3390/cancers 12123701.

Impactfactor: 6,126

## 4.2 Proefschriften en promoties

**Legué LM**. Clinical and pathological aspects of small bowel and appendiceal cancer: insights into rare entities. Rotterdam: Erasmus Universiteit; 21 februari 2020. Promotor: **VE Lemmens**. Copromotoren: GJ Creemers, **FN van Erning**.

## 5 Gynaecologische tumoren

### 5.1 Publicaties met impactfactor

Burg L, **Timmermans M, van der Aa MA**, Boll D, Rovers K, de Hingh I, van Altena A. Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands. *J Gynecol Oncol*. 2020 Sep;31(5):e58. doi: 10.3802/jgo.2020.31.e58. Impactfactor: 3,304

Glubb DM, Thompson DJ, **Aben KK**, Alsulimani A, Amant F, Annibaldi D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjørge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Bützow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen X, Chen Z, Cook LS, Cunningham JM, De Vivo I, DeFazio A, Doherty JA, Dork T, du Bois A, Dunning AM, Durst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Velez Edwards D, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA. **Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers.** *Cancer Epidemiol Biomarkers Prev*. 2020 Nov 3:cebp.0739.2020. doi: 10.1158/1055-9965.EPI-20-0739. Impactfactor: 4,344

Hermens M, van Altena AM, **van der Aa MA**, Bulten J, van Vliet HA, Siebers AG, Bekkers RL. **Ovarian cancer prognosis in women with endometriosis. A retrospective nationwide cohort study of 32,419 women.** *Am J Obstet Gynecol*. 2020 Aug 22:S0002-9378(20)30883-8. doi: 10.1016/j.ajog.2020.08.056. Impactfactor: 6,502

Poort H, **de Rooij BH**, Uno H, Weng S, **Ezendam NP, van de Poll-Franse LV**, Wright AA. Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study. *Cancer*. 2020 May 21. doi: 10.1002/cncr.32927. Online ahead of print. Impactfactor: 5,772

Post CC, de Boer SM, Powell ME, Mileshekin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger NP, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Kitchener HC, Nijman HW, Lutgens LC, Brooks S, Jürgenliemk-Schulz IM, Feeney A, Goss G, Fossati R, Ghatage P, Leary A, Do V, Lissoni AA, McCormack M, Nout RA, **Verhoeven-Adema KW**, Smit VT, Putter H, Creutzberg CL. **Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial.** *Int J Radiat Oncol Biol Phys*. 2020 Oct 28:S0360-3016(20)34447-3. doi: 10.1016/j.ijrobp.2020.10.030. Online ahead of print. Impactfactor: 5,859

van den Heerik AS, Horeweg N, Nout RA, Lutgens LC, van der Steen-Banasik EM, Westerveld GH, van den Berg HA, Slot A, Koppe FL, Kommos S, Mens JW, Nowee ME, Bijmolt S, Cibula D, Stam TC, Jürgenliemk-Schulz IM, Snyers A, Hamann M, Zwanenburg AG, Coen VL, Vandecasteele K, Gillham C, Chargari C, **Verhoeven-Adema KW**, Putter H, van den Hout WB, Wortman BG, Nijman HW, Bosse T, Creutzberg CL. **PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.** *Int J Gynecol Cancer*. 2020 Dec;30(12):2002-2007. doi: 10.1136/ijgc-2020-001929. Epub 2020 Oct 12. Impactfactor: 2,095

van Soolingen NJ, Smorenburg CH, Hamaker ME, Groen WG, Retèl VP, Lok CA, [van de Poll-Franse LV](#), Trum JW. GERiatric Screening in the treatment of elderly patients with Ovarian Carcinoma (GERSOC): study protocol for a pragmatic, cluster randomised controlled trial. *Trials*. 2020 Feb 22;21(1):214. doi: 10.1186/s13063-020-4157-y. Impactfactor: 1,883

van Walree IC, Hamaker ME, [de Rooij BH](#), Boll D, van Huis-Tanja LH, Emmelot-Vonk MH, [Ezendam NP](#). Do age and comorbidity impair recovery during two years after treatment for endometrial cancer? *J Geriatr Oncol*. 2020 Mar 10. pii: S1879-4068(19)30480-1. doi: 10.1016/j.jgo.2020.02.012. [Epub ahead of print] Impactfactor: 2,761

van Walree IC, [Bretveld R](#), van Huis-Tanja LH, Louwers JA, Emmelot-Vonk MH, Hamaker ME. Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer. *Gynecol Oncol*. 2020 Mar 11. pii: S0090-8258(20)30221-3. doi: 10.1016/j.ygyno.2020.03.005. [Epub ahead of print] Impactfactor: 4,623

van Weelden WJ, Reijnen C, Eggink FA, Boll D, Ottevanger PB, van den Berg HA, [van der Aa MA](#), Pijnenborg JM. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study. *Eur J Cancer*. 2020 May 23;133:104-111. doi: 10.1016/j.ejca.2020.04.012. Online ahead of print. Impactfactor: 7,275

[Wenzel HH](#), Van Kol KG, Nijman HW, [Lemmens VE](#), [van der Aa MA](#), Ebisch RM, Bekkers RL. Cervical cancer with  $\leq 5$  mm depth of invasion and  $> 7$  mm horizontal spread - Is lymph node assessment only required in patients with LVSI? *Gynecol Oncol*. 2020 May 4. pii: S0090-8258(20)31015-5. doi: 10.1016/j.ygyno.2020.04.705. [Epub ahead of print] Impactfactor: 4,623

[Wenzel HH](#), Kruitwagen RR, Nijman HH, Bekkers RR, Van Gorp T, de Kroon CC, van Lonkhuijzen LL, Massuger LL, Smolders RR, van Trommel NN, Yigit RR, Zweemer RR, [van der Aa MM](#). Short-term surgical complications after radical hysterectomy - a nationwide cohort study. *Acta Obstet Gynecol Scand*. 2020 Jan 18. doi: 10.1111/aogs.13812. [Epub ahead of print] Impactfactor: 2,770

[Wenzel HH](#), Smolders RG, Beltman JJ, Lambrechts S, Trum HW, Yigit R, Zusterzeel PL, Zweemer RP, Mom CH, Bekkers RL, [Lemmens VE](#), Nijman HW, [van der Aa MA](#). Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review. *Eur J Cancer*. 2020 May 15;133:14-21. doi: 10.1016/j.ejca.2020.04.006. Impactfactor: 7,275

## 6 Hemato-oncologie

### 6.1 Publicaties met impactfactor

**Arts LP, Oerlemans S**, Posthuma EF, Issa DE, Oosterveld M, van der Griend R, Nijziel MR, **van de Poll-Franse LV**. Web-based self-management for patients with lymphoma: assessment of the reach of intervention of a randomized controlled trial. *J Med Internet Res*. 2020 May 14;22(5):e17018. doi: 10.2196/17018.

Impactfactor: 5,034

de Vries S, **Schaapveld M**, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen RWM, Zijlstra JM, Beijert M, Nijziel MR, Verschueren KMS, Kremer LCM, van Eggermond AM, Lugtenburg PJ, Krol ADG, Roesink JM, Plattel WJ, van Spronsen DJ, van Imhoff GW, de Boer JP, Aleman BMP, van Leeuwen FE. *Long-term cause-specific mortality in hodgkin lymphoma patients*. *J Natl Cancer Inst*. 2020 Dec 22:djaa194. doi: 10.1093/jnci/djaa194. Online ahead of print.

Impactfactor: 11,577

**Dinnessen MA**, van der Poel MW, Tonino SH, **Visser O**, Blijlevens NM, de Jong D, Lam KH, Kersten MJ, Lugtenburg PJ, **Dinmohamed AG**. Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016. *Leukemia*. 2020 Oct 12. doi: 10.1038/s41375-020-01048-6. Online ahead of print.

Impactfactor: 8,665

Dong D, Jin J, **Oerlemans S**, Yu S, Yang S, Zhu J, Xu RH. Validation of the Chinese EORTC chronic lymphocytic leukaemia module - application of classical test theory and item response theory. *Health Qual Life Outcomes*. 2020 Apr 7;18(1):96. doi: 10.1186/s12955-020-01341-z.

Impactfactor: 2,344

Driessen J, **Visser O**, Zijlstra JM, Lugtenburg PJ, Plattel WJ, Kersten MJ, **Dinmohamed AG**. Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017. *Leukemia*. 2020 May 28. doi: 10.1038/s41375-020-0875-0. Online ahead of print.

Impactfactor: 8,665

**Ector GI, Visser O**, Westerweel PE, Janssen JJ, Blijlevens NM, **Dinmohamed AG**. Correction: Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017. *Leukemia*. 2020 Sep 28. doi: 10.1038/s41375-020-01040-0. Online ahead of print.

Impactfactor: 8,665

**Ector GI, Visser O**, Westerweel PE, Janssen JJ, Blijlevens NM, **Dinmohamed AG**. Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017. *Leukemia*. 2020 Jun 8. doi: 10.1038/s41375-020-0902-1. Online ahead of print.

Impactfactor: 8,665

Efficace F, Iurlo A, Patriarca A, Stagno F, Bee PC, Ector G, Capodanno I, Elena C, Bonifacio M, Blijlevens NMA, Caocci G, Wan C, Abruzzese E, Breccia M, Cottone F, Okumura I, **Oerlemans S**, Cascavilla N, Albano F, Kota V, Sztankay M, Miggiano MC, Saussele S, Di Renzo N, Sorà F, Castagnetti F, Baccarani M, Vignetti M, Rosti G. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. *Leuk Lymphoma*. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1838509. Online ahead of print.

Impactfactor: 2,969

Issa DE, **Dinmohamed AG**, Wondergem MJ, Blommestein HM, **Huijgens PC**, Lugtenburg PJ, **Visser O**, Zweegman S, Chamuleau ME. A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. *Leuk Lymphoma*. 2020 Nov 19:1-11. doi: 10.1080/10428194.2020.1842394. Online ahead of print.

Impactfactor: 2,969

Reedijk AM, Zijregtop EA, Coebergh JW, Meyer-Wentrup FA, Hebeda KM, Zwaan CM, Janssens GO, Pieters R, Plattel WJ, **Dinmohamed AG**, Zijlstra JM, Kremer LC, Lugtenburg PJ, Beishuizen A, **Karim-Kos HE**. Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015. *Br J Haematol*. 2020 Feb 6. doi: 10.1111/bjh.16491. [Epub ahead of print]  
Impactfactor: 5,518

Reedijk AM, Coebergh JW, de Groot-Kruseman HA, van der Sluis IM, Kremer LC, **Karim-Kos HE**, Pieters R. Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015. *Leukemia*. 2020 Aug 21. doi: 10.1038/s41375-020-01024-0. Online ahead of print.  
Impactfactor: 8,665

Schoormans D, Jansen M, **Mols F, Oerlemans S**. Negative illness perceptions are related to more fatigue among haematological cancer survivors: a PROFILES study. *Acta Oncol*. 2020 May 15:1-8. doi: 10.1080/0284186X.2020.1759823.  
Impactfactor: 3,701

Stege CAM, van der Holt B, **Dinmohamed AG**, Sonneveld P, Levin MD, van de Donk NWCJ, Mellqvist UH, Waage A, Zweegman S. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. *Leukemia*. 2020 Jan 22. doi: 10.1038/s41375-020-0713-4. [Epub ahead of print] No abstract available.  
Impactfactor: 8,665

Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Čermák J, **Dinmohamed AG**, Eeltink C, Eggmann S, Fenaux P, Germing U, Haschke M, Hellstrom-Lindberg E, Heger M, van de Loosdrecht AA, Passweg J, Pfeilstöcker M, Platzbecker U, Malcovati L, de Almeida AM, Mittelman M, Morgenthaler C, Steensma DP, Santini V, Stauder R, Symeonidis A, Schär S, Maddox C, de Witte T, Bohlius J, Bonadies N. Guideline-based indicators for adult patients with myelodysplastic syndromes. *Blood Adv*. 2020 Aug 25;4(16):4029-4044. doi: 10.1182/bloodadvances.2020002314.  
Impactfactor: 4,910

van der Meulen M, Bromberg JEC, Nijland M, **Visser O**, Doorduijn JK, **Dinmohamed AG**. Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands. *Haematologica*. 2020 Apr 2. pii: haematol.2020.247536. doi: 10.3324/haematol.2020.247536. [Epub ahead of print] No abstract available.  
Impactfactor: 7,116

**van der Straten L**, Kater AP, Doorduijn JK, van den Broek EC, Posthuma EF, **Dinmohamed AG**, Levin MD. Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia. *Ann Hematol*. 2020 Mar 19. doi: 10.1007/s00277-020-03994-8. [Epub ahead of print]  
Impactfactor: 2,904

**van der Straten L**, Levin MD, **Visser O**, Posthuma EF, Doorduijn JK, Kater AP, **Dinmohamed AG**. Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016. *Br J Haematol*. 2020 Jan 20. doi: 10.1111/bjh.16397. [Epub ahead of print] No abstract available.  
Impactfactor: 5,518

**van der Straten L**, Levin MD, **Visser O**, Blijlevens NM, Cornelissen JJ, Doorduijn JK, Kater AP, **Dinmohamed AG**. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands. *Br J Haematol*. 2020 Jan 28. doi: 10.1111/bjh.16391. [Epub ahead of print] No abstract available.  
Impactfactor: 5,518

van Lieshout R, Tick LW, de Laat D, Custers S, Dekker IM, Douma MD, Kalter D, Kranenburg S, van der Lee D, Rhoon-Bruijnzeel P, Schlösser I, Somer M, van Tilborg CJ, Visser WK, Schouten HC, **Beijer S**. Adherence to guidelines on nutrition support during intensive treatment of acute myeloid leukemia patients: a nationwide comparison. *Clin Nutr ESPEN*. 2020 Oct;39:242-250. doi: 10.1016/j.clnesp.2020.05.003. Epub 2020 Aug 3.  
Impactfactor: 6,360



van Lieshout R, Tick LW, Dieleman JP, Custers S, van Dongen MS, van der Lee D, **Schaaphok AR**, **Snellen M**, Schouten HC, **Beijer S**. Changes in body weight and serum liver tests associated with parenteral nutrition compared with no parenteral nutrition in patients with acute myeloid leukemia during remission induction treatment. *Support Care Cancer*. 2020 Jan 8. doi: 10.1007/s00520-019-05251-9. [Epub ahead of print]  
Impactfactor: 2,635

## 6.2 Overige publicaties

**Dinmohamed AG**, van der Meulen M, **Visser O**, Doorduijn JK, Bromberg JE. Conditional relative survival in primary central nervous system lymphoma: a population-based study in the Netherlands. *Neurooncol Adv*. 2020 Oct 1;2(1):vdaa133. doi: 10.1093/oaajnl/vdaa133. eCollection 2020 Jan-Dec. PMID: 33235997 Free PMC article. No abstract available.

Liu L, Neven A, Giusti F, Maraldo MV, Meijnders P, Aurer I, Fortpied C, Collette L, **Visser O**. Using both clinical research and population-based cancer registry in long-term research: a case study using EORTC trials and the Dutch national cancer registry (IKNL). *J Cancer Policy*. 2020 June;24:100226.

**Oerlemans S**, Bennink MC, Levin MD, Broijl A, van der Klift M, van Deursen J, Vogels D, **van de Poll-Franse LV**, Sonneveld P, Hazelzet JA, Tick LW. Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice. *Hemasphere*. 2020 May 27;4(3):e366. doi: 10.1097/HS9.0000000000000366. eCollection 2020 Jun. No abstract available.

## 6.3 Proefschriften en promoties

**Arts LP**. Psychological distress among lymphoma survivors: from inventory to intervention. Tilburg: Tilburg University; 24 juni 2020. Promotor: **LV van de Poll-Franse**. Copromotores: **S Oerlemans**, EF Posthuma. Commissieleden: T Smeets, HC van Weert, **S Siesling**, NM Blijlevens, ML van der Lee, **NP Ezendam**.

## 7 Hoofdhalskanker

### 7.1 Publicaties met impactfactor

Brands M, Verbeek A, Geurts S, **Merkx MA**. Follow-up after oral cancer treatment transition to a personalised approach. *J Oral Pathol Med*. 2020 Dec 3. doi: 10.1111/jop.13147. Online ahead of print. Impactfactor: 2,495

de Groot RJ, Rieger JM, Rosenberg AJ, **Merkx MA**, Speksnijder CM. A pilot study of masticatory function after maxillectomy comparing rehabilitation with an obturator prosthesis and reconstruction with a digitally planned, prefabricated, free, vascularized fibula flap. *J Prosthet Dent*. 2020 Nov;124(5):616-622. doi: 10.1016/j.prosdent.2019.06.005. Epub 2020 Jan 17. Impactfactor: 2,444

Dieleman FJ, Meijer GJ, **Merkx MA**. Does hyperbaric oxygen therapy play a role in the management of osteoradionecrosis? a survey of Dutch oral and maxillofacial surgeons. *Int J Oral Maxillofac Surg*. 2020 Jul 13:S0901-5027(20)30238-1. doi: 10.1016/j.ijom.2020.06.014. Online ahead of print. Impactfactor: 2,068

Dings JP, Vijverberg MA, Hol MK, Ulrich DJ, de Haan AF, Verhage-Damen GW, de Clonie MacLennan-Naphausen MT, Kruyt IJ, Ghaemina H, Bruekers-Schipper GB, Ingels KJ, Dicker GJ, Meijer GJ, **Merkx MA**. Autologous versus prosthetic nasal and auricular reconstruction - patient, professional and layperson perceptions. *Int J Oral Maxillofac Surg*. 2020 Mar 13:S0901-5027(20)30078-3. doi: 10.1016/j.ijom.2020.02.010. Online ahead of print. Impactfactor: 2,068

**Geleijnse G**, Chiang RC, **Sieswerda M**, **Schuurman M**, Lee KC, van Soest J, Dekker A, Lee WC, **Verbeek XA**. Prognostic factors analysis for oral cavity cancer survival in the Netherlands and Taiwan using a privacy-preserving federated infrastructure. *Sci Rep*. 2020 Nov 25;10(1):20526. doi: 10.1038/s41598-020-77476-2. Impactfactor: 3,998

Husson O, Poort H, Sansom-Daly UM, Netea-Maier R, Links T, **Mols F**. Psychological Distress and Illness Perceptions in Thyroid Cancer Survivors: Does Age Matter? *J Adolesc Young Adult Oncol*. 2020 Jan 28. doi: 10.1089/jayao.2019.0153. [Epub ahead of print] Impactfactor: 1,599

Lobeek D, Rijpkema M, Terry SY, Molkenboer-Kuening JD, Joosten L, van Genugten EA, van Engen-van Grunsven AC, Kaanders JH, Pegge SA, Boerman OC, Weijs WL, **Merkx MA**, van Herpen CM, Takes RP, Aarntzen EH, Oyen WJ. Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [<sup>68</sup>Ga]Ga-DOTA-E-[c(RGDfK)]<sub>2</sub> PET/CT. *Eur J Nucl Med Mol Imaging*. 2020 Mar 20. doi: 10.1007/s00259-020-04766-2. Online ahead of print. PMID: 32198613. Impactfactor: 7,081

**Mols F**, Thong M, Denollet J, Oranje WA, Netea-Maier RT, Smit JW, Husson O. Are illness perceptions, beliefs about medicines and Type D personality associated with medication adherence among thyroid cancer survivors? a study from the population-based PROFILES registry. *Psychol Health*. 2020 Feb;35(2):128-143. doi: 10.1080/08870446.2019.1619730. Epub 2019 May 25. Impactfactor: 2,528

Schoormans D, Wijnberg L, Haak H, Husson O, **Mols F**. Negative illness perceptions are related to poorer health-related quality of life among thyroid cancer survivors: results from the PROFILES registry. *Head Neck*. 2020 Jun 3. doi: 10.1002/hed.26290. Online ahead of print. Impactfactor: 2,538

Schutte HW, van den Broek GB, Steens SC, Hermens RP, Honings J, Marres HA, **Merkx MA**, Weijs WL, Arens AIJ, van Engen-van Grunsven AC, van Herpen CM, Kaanders JH, van den Hoogen FJ, Takes RP. Impact of optimizing diagnostic workup and reducing the time to treatment in head and neck cancer. *Cancer*. 2020 Sep 1;126(17):3982-3990. doi: 10.1002/cncr.33037. Epub 2020 Jul 7. Impactfactor: 5,772

Speksnijder CM, Lankhorst PJ, de Bree R, de Haan AF, Koole R, **Merks MA**. Depression and related factors after oral oncological treatment: a 5-year prospective cohort study. Support Care Cancer. 2020 Oct 1. doi: 10.1007/s00520-020-05795-1. Online ahead of print.  
Impactfactor: 2,635

Takes RP, Halmos GB, Ridge JA, Bossi P, **Merks MA**, Rinaldo A, Sanabria A, Smeele LE, Mäkitie AA, Ferlito A. Value and quality of care in head and neck oncology. Curr Oncol Rep. 2020 Jul 10;22(9):92. doi: 10.1007/s11912-020-00952-5.  
Impactfactor: 3,828

Valstar MH, Schaapveld M, van den Broek EC, van Velthuysen MF, de Ridder M, Schmidt MK, **van Dijk BA**, Balm AJ, Smeele LE. Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands. Cancer Med. 2020 Nov 28. doi: 10.1002/cam4.3598. Online ahead of print.  
Impactfactor: 3,491

van der Kamp MF, Muntinghe FO, Iepsma RS, Plaat BE, van der Laan BF, Algassab A, Steenbakkens RJ, Witjes MJ, **van Dijk BA**, de Bock GH, Halmos GB. Predictors for distant metastasis in head and neck cancer, with emphasis on age. Eur Arch Otorhinolaryngol. 2020 Jun 15. doi: 10.1007/s00405-020-06118-0. Online ahead of print.  
Impactfactor: 1,809

van Dijk D, **van Dijk BA**, Weistra A, Links TP, Plukker JT. Surgical Complications and Referral Patterns in 567 Patients with Differentiated Thyroid Cancer in the Northern Region of the Netherlands: A Population-Based Study Towards Clinical Management Implementation. Ann Surg Oncol. 2020 Apr 23. doi: 10.1245/s10434-020-08470-1. [Epub ahead of print]  
Impactfactor: 4,061

van Hinte G, Leijendekkers RA, Te Molder B, Jansen L, Bol C, **Merks MA**, Takes R, Nijhuis-van der Sanden MWG, Speksnijder CM. Reproducibility of measurements on physical performance in head and neck cancer survivors; measurements on maximum mouth opening, shoulder and neck function, upper and lower body strength, level of physical mobility, and walking ability. PLoS One. 2020 Sep 3;15(9):e0233271. doi: 10.1371/journal.pone.0233271. eCollection 2020.  
Impactfactor: 2,740

## 7.2 Overige publicaties

Beunk L, **Merks MA**, Meijer GJ. Factoren die bijdragen aan het delay in het diagnostisch proces van een mondholletumor. Ned. Tijdschr Tandheelkd. 2020 Sep;127(9):493-498. doi: 10.5177/ntvt.2020.09.20023.

## 7.3 Proefschriften en promoties

Brands MT. Follow-up after the curative treatment of oral squamous cell carcinoma in the Netherlands: transition to a personalized approach. Nijmegen: Radboud Universiteit; 2 oktober 2020. Promotoren: **MA Merks**, AL Verbeek. Copromotor: SM Geurts. Manuscriptcommissie: GP Westert, **VE Lemmens**, HA Marres.

## 8 Huidkanker

### 8.1 Publicaties met impactfactor

Boekhout AH, Rogiers A, Jozwiak K, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JW, Aarts MJ, Kapiteijn E, Ten Tije AJ, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KP, Rozeman EA, Neyns B, Janssen KJ, [van de Poll-Franse LV](#), Blank CU. Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. *Acta Oncol.* 2020 Sep 14;1-9. doi: 10.1080/0284186X.2020.1818823. Online ahead of print.  
Impactfactor: 3,701

[Hollestein LM](#), Nijsten T. Survival is excellent for most patients with thin melanoma, but patients may die from thin melanoma. *Br J Dermatol.* 2020 Jun 15. doi: 10.1111/bjd.19208. Online ahead of print.  
Impactfactor: 7,0

Moncrieff M, Underwood B, Garioch J, Heaton M, Patel N, Bastiaannet E, [Hoekstra-Weebers J](#), Hoekstra H. ASO author reflections: the MelFo-study, UK: effects of a reduced frequency, stage-adjusted follow-up schedule for cutaneous melanoma IB-IIC patients after 3 years. *Ann Surg Oncol.* 2020 Oct;27(11):4120-4121. doi: 10.1245/s10434-020-08763-5. Epub 2020 Jul 10. PMID: 32651698 Free PMC article. No abstract available.  
Impactfactor: 4,061

Moncrieff MD, Underwood B, Garioch JJ, Heaton M, Patel N, Bastiaannet E, [Hoekstra-Weebers JE](#), Hoekstra HJ. The MelFo Study UK: effects of a reduced-frequency, stage-adjusted follow-up schedule for cutaneous melanoma 1B to 2C patients after 3-years. *Ann Surg Oncol.* 2020 Jul 4. doi: 10.1245/s10434-020-08758-2. Online ahead of print.  
Impactfactor: 4,061

Noels E, [Hollestein L](#), Luijckx K, [Louwman MW](#), de Uyl-de Groot C, van den Bos R, van der Veldt A, Grünhagen D, Wakkee M. Increasing costs of skin cancer due to increasing incidence and introduction of pharmaceuticals, 2007-2017. *Acta Derm Venereol.* 2020 May 28;100(10):adv00147. doi: 10.2340/00015555-3463.  
Impactfactor: 4,016

Tokez S, Wakkee M, [Louwman MW](#), [Noels E](#), Nijsten T, [Hollestein L](#). Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In Situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In Situ vs the General Population in the Netherlands, 1989-2017. *JAMA Dermatol.* 2020 Jul 1:e201988. doi: 10.1001/jamadermatol.2020.1988. Online ahead of print.  
Impactfactor: 7,738

Tokez S, [Hollestein LM](#), [Louwman MW](#), Nijsten T, [Wakkee M](#). Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma. *JAMA Dermatol.* 2020 Oct 28. doi: 10.1001/jamadermatol.2020.3677. Online ahead of print.  
Impactfactor: 7,738

### 8.2 Overige publicaties

Deckers EA, [Louwman MW](#), Kruijff S, Hoekstra HJ. Increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. *Melanoma Manag.* 2020 Mar 30;7(1):MMT38. doi: 10.2217/mmt-2019-0018.

Deckers EA, [Louwman MW](#), Kruijff S, Hoekstra HJ. Letter in reply: increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. *Melanoma Manag.* 2020 Nov 23;8(1):MMT53. doi: 10.2217/mmt-2020-0021. PMID: 33552469 Free PMC article. No abstract available.

---

Nijsten T, [Hollestein L](#). Incidentie van melanomen bij jongeren: mag het een beetje minder zijn? NtvG 2020 mei;164(19):13-16.

## 9 Longkanker

### 9.1 Publicaties met impactfactor

Bousema JE, [Aarts MJ](#), Dijkgraaf MG, Annema JT, van den Broek FJ. Trends in mediastinal nodal staging and its impact on unforeseen N2 and survival in lung cancer. *Eur Respir J*. 2020 Oct 2:2001549. doi: 10.1183/13993003.01549-2020. Online ahead of print. Impactfactor: 12,339

Brancher S, Støer NC, Weiderpass E, [Damhuis RA](#), Johannesen TB, Botteri E, Strand TE. Metformin use and lung cancer survival: a population-based study in Norway. *Br J Cancer*. 2020 Dec 2. doi: 10.1038/s41416-020-01186-9. Online ahead of print. Impactfactor: 5,791

Buikhuisen WA, Steinbusch LC, Kodach LL, Tesselaar ME, [Damhuis RA](#). Risk of second primary malignancies among patients with carcinoid of the lung. *Lung Cancer*. 2020 Nov 19;151:5-7. doi: 10.1016/j.lungcan.2020.11.017. Online ahead of print. Impactfactor: 4,702

de Man Y, Groenewoud S, Oosterveld-Vlug MG, [Brom L](#), Onwuteaka-Philipsen BD, Westert GP, Atsma F. Regional variation in hospital care at the end-of-life of Dutch patients with lung cancer exists and is not correlated with primary and long-term care. *Int J Qual Health Care*. 2020 Mar 18. pii: mzaa004. doi: 10.1093/intqhc/mzaa004. [Epub ahead of print] Impactfactor: 1,957

de Ruiter JC, Heineman DJ, de Langen AJ, Dahele M, [Damhuis RA](#), Hartemink KJ. Centralization of lung cancer surgery in the Netherlands: differences in care and survival of patients with stage I non-small cell lung cancer between hospitals with and without in-house lung cancer surgery. *Acta Oncol*. 2020 Jan 7:1-4. doi: 10.1080/0284186X.2019.1711168. [Epub ahead of print] No abstract available. Impactfactor: 3,701

de Ruiter JC, Heineman DJ, Daniels JM, van Diessen JN, [Damhuis RA](#), Hartemink KJ. The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands. *Lung Cancer*. 2020 Apr 19;144:64-70. doi: 10.1016/j.lungcan.2020.04.005. [Epub ahead of print] Impactfactor: 4,702

Gijtenbeek RG, [Damhuis RA](#), Groen HJ, van der Wekken AJ, van Geffen WH. Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer. *Clin Lung Cancer*. 2020 May 22:S1525-7304(20)30159-5. doi: 10.1016/j.clcc.2020.05.019. Online ahead of print. Impactfactor: 3,550

Joosten PJ, [Damhuis RA](#), van Diessen JN, de Langen JA, Belderbos JS, Smit EF, Klomp HM, Veenhof AA, Hartemink KJ. Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands. *Acta Oncol*. 2020 Apr 29:1-5. doi: 10.1080/0284186X.2020.1757150. [Epub ahead of print] Impactfactor: 3,701

Moonen L, Derks JL, Hermans BC, Bunnik IM, Hillen LM, Jan van Suylen R, den Bakker MA, von der Thüsen JH, [Damhuis RA](#), van den Broek EC, Buikhuisen WA, Dingemans AC, Speel EJ. Pre-operative biopsy diagnosis in pulmonary carcinoids, a shot in the dark. *J Thorac Oncol*. 2020 Dec 14:S1556-0864(20)31106-0. doi: 10.1016/j.jtho.2020.12.004. Online ahead of print. Impactfactor: 13,357

---

## 9.2 Overige publicaties

**Sieswerda MS**, Bermejo I, **Geleijnse G**, **Aarts MJ**, **Lemmens VE**, De Ruyscher D, Dekker AL, **Verbeek XA**. Predicting Lung Cancer Survival Using Probabilistic Reclassification of TNM Editions With a Bayesian Network. *JCO Clin Cancer Inform.* 2020 May;4:436-443. doi: 10.1200/CCI.19.00136.

---

## 10 Neuro-endocriene tumoren

### 10.1 Publicaties met impactfactor

Hermans BC, de Vos-Geelen J, Derks JL, Latten L, Liem IH, [van der Zwan JM](#), Speel EM, Dercksen MW, Dingemans AC. [Unique metastatic patterns in neuroendocrine neoplasms of different primary origin.](#) *Neuroendocrinology*. 2020 Nov 23. doi: 10.1159/000513249. Online ahead of print. Impactfactor: 4,271

Zandee WT, [van der Zwan JM](#), de Herder WW, van Velthuysen MF. [Importance of complete pathology reporting for neuroendocrine carcinoma: WHO guidelines are a good start but not enough.](#) *Neuroendocrinology*. 2020; 110(11-12):994-1000. doi: 10.1159/000505920. Epub 2020 Jan 28. Impactfactor: 4,271



# 11 Upper GI & HPB

## 11.1 Publicaties met impactfactor

Al-Kaabi A, Schoon EJ, Deprez PH, Seewald S, Groth S, Giovannini M, Braden B, Berr F, Lemmers A, Hoare J, Bhandari P, van der Post RS, **Verhoeven RH**, Siersema PD. *Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience*. *Gastrointest Endosc*. 2020 Aug 4:S0016-5107(20)34657-5. doi: 10.1016/j.gie.2020.07.062. Online ahead of print. Impactfactor: 6,890

de Savornin Lohman EA, Kuipers H, van Dooren M, **Verhoeven RH**, Erdmann JI, Groot Koerkamp B, Braat AE, Hagendoorn J, Daams F, van Dam R, van Gulik TM, de Boer MT, de Reuver PR. *Should jaundice preclude resection in patients with gallbladder cancer? Results from a nation-wide cohort study*. *HPB (Oxford)*. 2020 Apr 24. pii: S1365-182X(20)30099-X. doi: 10.1016/j.hpb.2020.03.015. [Epub ahead of print] Impactfactor: 3,401

de Savornin Lohman E, de Bitter T, **Verhoeven RH, van der Geest LG**, Hagendoorn J, Haj Mohammad N, Daams F, Klümpen HJ, van Gulik T, Erdmann J, de Boer M, Hoogwater F, Koerkamp BG, Braat A, Verheij J, Nagtegaal I, van Laarhoven C, van den Boezem P, van der Post R, de Reuver P. *Trends in treatment and survival of gallbladder cancer in the Netherlands: identifying gaps and opportunities from a nation-wide cohort*. *Cancers (Basel)*. 2020 Apr 9;12(4). pii: E918. doi: 10.3390/cancers12040918. Impactfactor: 6,126

de Vos-Geelen J, Hoebers FJ, Geurts SM, Hoeben A, de Greef BT, Voncken FE, Bogers JHA, Braam PM, Muijs CK, de Jong MA, Kasperts N, Rozema T, Jeene PM, Blom GJ, van Dieren JM, Hulshof MC, van Laarhoven HW, Grabsch HI, **Lemmens VE**, Tjan-Heijnen VC, Nieuwenhuijzen GA. *A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer*. *Acta Oncol*. 2020 Apr 22:1-9. doi: 10.1080/0284186X.2020.1753889. [Epub ahead of print] Impactfactor: 3,701

**Dijksterhuis WP, Verhoeven RH, Pape M**, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, **Lemmens VE, van Oijen MG**, van Laarhoven HW. *Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: a population-based study*. *Eur J Cancer*. 2020 Sep 24;139:107-118. doi: 10.1016/j.ejca.2020.08.010. Online ahead of print. Impactfactor: 7,275

**Dijksterhuis WP, Verhoeven RH**, Meijer SL, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, **van Oijen MG**, van Laarhoven HW. *Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study*. *Gastric Cancer*. 2020 Jan 11. doi: 10.1007/s10120-020-01039-7. [Epub ahead of print] Impactfactor: 7,088

Gertsen EC, Borggreve AS, Brenkman HJ, **Verhoeven RH**, Vegt E, van Hillegersberg R, Siersema PD, Ruurda JP; Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group. *Evaluation of the implementation of FDG-PET/CT and staging laparoscopy for gastric cancer in the Netherlands*. *Ann Surg Oncol*. 2020 Sep 8. doi: 10.1245/s10434-020-09096-z. Online ahead of print. Impactfactor: 4,061

Gertsen EC, Brenkman HJ, Brosens LA, **Luijten JC**, Mohammad NH, **Verhoeven RH**, van Hillegersberg R, Ruurda JP. *Refraining from resection in patients with potentially curable gastric carcinoma*. *Eur J Surg Oncol*. 2020 Oct 22:S0748-7983(20)30862-3. doi: 10.1016/j.ejso.2020.10.025. Online ahead of print. Impactfactor: 3,959

Groen JV, Douwes TA, van Eycken E, [van der Geest LG](#), Johannesen TB, Besselink MG, Koerkamp BG, Wilmink JW, Bonsing BA, Portielje JE, van de Velde CJ, Bastiaannet E, Mieog JS; Dutch Pancreatic Cancer Group. [Treatment and survival of elderly patients with Stage I-II pancreatic cancer: a report of the EURECCA Pancreas Consortium](#). *Ann Surg Oncol*. 2020 May 9. doi: 10.1245/s10434-020-08539-x. Online ahead of print.

Impactfactor: 4,061

Huang L, Jansen L, Balavarca Y, [Verhoeven RH](#), Ruurda JP, Van Eycken L, De Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Mägi M, Bastiaannet E, Lagarde SM, van de Velde CJ, Schrotz-King P, Brenner H. [Decreasing resection rates for nonmetastatic gastric cancer in Europe and the United States](#). *Clin Transl Med*. 2020 Oct;10(6):e203. doi: 10.1002/ctm2.203.

Impactfactor: 7,919

Kalff MC, Fransen LF, de Groot EM, Gisbertz SS, Nieuwenhuijzen GA, Ruurda JP, [Verhoeven RH](#), Luyer MD, van Hillegerberg R, van Berge Henegouwen MI; Dutch Upper Gastrointestinal Cancer Audit group. [Long-term survival after minimally invasive versus open esophagectomy for esophageal cancer: a nationwide propensity-score matched analysis](#). *Ann Surg*. 2020 Dec 23; Publish Ahead of Print. doi: 10.1097/SLA.0000000000004708. Online ahead of print.

Impactfactor: 10,13

Koemans WJ, [Luijten JC](#), van der Kaaij RT, Grootscholten C, Snaebjornsson P, [Verhoeven RH](#), van Sandick JW. [The metastatic pattern of intestinal and diffuse type gastric carcinoma: a Dutch national cohort study](#). *Cancer Epidemiol*. 2020 Oct 27;69:101846. doi: 10.1016/j.canep.2020.101846. Online ahead of print.

Impactfactor: 2,179

Latenstein AE, [Dijksterhuis WP](#), Mackay TM, [Beijer S](#), van Eijck CH, de Hingh IH, Molenaar IQ, [van Oijen MG](#), van Santvoort HC, de van der Schueren MA, de Vos-Geelen J, de Vries JH, Wilmink JW, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group. [Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: a multicenter cohort study](#). *Cancer Med*. 2020 Oct 27. doi: 10.1002/cam4.3556. Online ahead of print.

Impactfactor: 3,491

Latenstein AE, van Roessel S, [van der Geest LG](#), Bonsing BA, Dejong CH, Groot Koerkamp B, de Hingh IH, Homs MY, Klaase JM, [Lemmens VE](#), Molenaar IQ, Steyerberg EW, Stommel MW, Busch OR, van Eijck CH, van Laarhoven HW, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. [Conditional survival after resection for pancreatic cancer: A population-based study and prediction model](#). *Ann Surg Oncol*. 2020 Feb 12. doi: 10.1245/s10434-020-08235-w. [Epub ahead of print]

Impactfactor: 4,061

Latenstein AE, Mackay TM, Creemers GJ, van Eijck CH, de Groot JW, Haj Mohammad N, Homs MY, van Laarhoven HW, Molenaar IQ, Ten Tije BJ, de Vos-Geelen J, Besselink MG, [van der Geest LG](#), Wilmink JW; Dutch Pancreatic Cancer Group. [Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis](#). *Acta Oncol*. 2020 Feb 14:1-8. doi: 10.1080/0284186X.2020.1725241. [Epub ahead of print]

Impactfactor: 3,701

Liu P, McMenamin ÚC, Johnston BT, Murchie P, Iversen L, Lee AJ, [Vissers PA](#), Cardwell CR. [Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies](#). *Br J Cancer*. 2020 May 5. doi: 10.1038/s41416-020-0860-4. [Epub ahead of print]

Impactfactor: 5,791

Mackay TM, Smits FJ, Latenstein AE, Bogte A, Bonsing BA, Bos H, Bosscha K, Brosens LA, Hol L, Busch OR, Creemers GJ, Curvers WL, den Dulk M, van Dieren S, van Driel LM, Festen S, van Geenen EJ, [van der Geest LG](#), de Groot DJ, de Groot JW, Haj Mohammad N, Haberkorn BC, Haver JT, van der Harst E, Hemmink GJ, de Hingh IH, Hoge C, Homs MY, van Huijgevoort NC, Jacobs MA, Kerver ED, Liem MS, Los M, Lubbinge H, Luelmo SA, de Meijer VE, Mekenkamp L, Molenaar IQ, van Oijen MG, Patijn GA, Quispel R, van Rijssen LB, Römkens TE, van Santvoort HC, Schreinemakers JM, Schut H, Seerden T, Stommel MW, Ten Tije AJ, Venneman NG, Verdonk RC, Verheij J, van Vilsteren FG, de Vos-Geelen J, Vulink A, Wientjes C, Wit F, Wessels FJ, Zonderhuis B, van Werkhoven CH, van Hooft JE, van Eijck CH, Wilmink JW, van Laarhoven HW, Besselink MG; Dutch Pancreatic Cancer Group. [Impact of nationwide enhanced](#)

implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial. *Trials*. 2020 Apr 16;21(1):334. doi: 10.1186/s13063-020-4180-z. Impactfactor: 1,883

Mackay TM, Latenstein AE, Bonsing BA, Bruno MJ, van Eijck CH, Groot Koerkamp B, **de Hingh IH**, Homs MY, van Hooft JE, van Laarhoven HW, Molenaar IQ, van Santvoort HC, Stommel MW, de Vos-Geelen J, Wilmink JW, Busch OR, **van der Geest LG**, Besselink MG. Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. *Pancreatology*. 2020 Oct 10:S1424-3903(20)30782-1. doi: 10.1016/j.pan.2020.10.032. Online ahead of print. Impactfactor: 3,629

Mackay TM, van Rijssen LB, Andriessen JO, Suker M, Creemers GJ, Eskens FA, de Hingh IH, **van de Poell-Franse LV**, Sprangers MA, Busch OR, Wilmink JW, van Eijck CH, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group. Patient satisfaction and quality of life before and after treatment of pancreatic and periampullary cancer: a prospective multicenter study. *J Natl Compr Canc Netw*. 2020 Jun;18(6):704-711. doi: 10.6004/jnccn.2020.7528. Impactfactor: 9,316

Mackay TM, Latenstein AE, Sprangers MA, **van der Geest LG**, Creemers GJ, van Dieren S, de Groot JB, Groot Koerkamp B, de Hingh IH, Homs MY, de Jong EJ, Molenaar IQ, Patijn GA, **van de Poell-Franse LV**, van Santvoort HC, de Vos-Geelen J, Wilmink JW, van Eijck CH, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group. Relationship between quality of life and survival in patients with pancreatic and periampullary cancer: a multicenter cohort analysis. *J Natl Compr Canc Netw*. 2020 Oct 1;18(10):1354-1363. doi: 10.6004 /jnccn.2020.7579. Print 2020 Oct. impactfactor: 9,316

Reinders MT, van Meer S, Burgmans MC, de Jong KP, Klumpen HJ, de Man RA, Ramsoekh DS, Sprengers D, Tjwa ET, de Vos-Geelen J, van Erpecum KJ, **van der Geest LG**; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG). Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country: Data from the Netherlands in the period 2009-2016. *Eur J Cancer*. 2020 Aug 13;137:214-223. doi: 10.1016/j.ejca.2020.07.008. Online ahead of print. Impactfactor: 7,275

van de Ven SE, Falger JM, **Verhoeven RH**, Baatenburg de Jong RJ, Spaander MC, Bruno MJ, Koch AD. Increased risk of second primary tumours in patients with oesophageal squamous cell carcinoma: a nationwide study in a Western population. *United European Gastroenterol J*. 2020 Dec 3: 2050640620977129. doi: 10.1177/2050640620977129. Impactfactor: 3,549

van der Kaaij RT, Koemans WJ, **van Putten M**, Snaebjornsson P, **Luijten JC**, van Dieren JM, Cats A, **Lemmens VE**, **Verhoeven RH**, van Sandick JW. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015. *Eur J Cancer*. 2020 Mar 11;130:23-31. doi: 10.1016/j.ejca.2020.02.017. [Epub ahead of print] Impactfactor: 7,275

van Kleef JJ, van den Boorn HG, **Verhoeven RH**, Vanschoenbeek K, Abu-Hanna A, Zwinderman AH, Sprangers MA, van Oijen MG, De Schutter H, van Laarhoven HW. External validation of the Dutch SOURCE survival prediction model in Belgian metastatic oesophageal and gastric cancer patients. *Cancers (Basel)*. 2020 Mar 31;12(4). pii: E834. doi: 10.3390/cancers12040834. Impactfactor: 6,126

Vermeulen BD, Bruggeman L, Bac DJ, Schrauwen RW, Epping LS, Scheffer RC, Tan AC, Groenen MJ, **Verhoeven RH**, Siersema PD. Impact of multidisciplinary tumor board discussion on palliation of patients with esophageal or gastro-esophageal junction cancer: a population-based study. *Acta Oncol*. 2020 Feb 18:1-7. doi: 10.1080/0284186X.2020.1725240. [Epub ahead of print] Impactfactor: 3,701

Versteijne E, Suker M, **Groothuis K**, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van

---

Eijck CH, van Tienhoven G; Dutch Pancreatic Cancer Group. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. *J Clin Oncol*. 2020 Feb 27;JCO1902274. doi: 10.1200/JCO.19.02274. [Epub ahead of print]  
Impactfactor: 32,956

## 11.2 Overige publicaties

Steen MW, van Rijssen LB, Festen S, Busch OR, Groot Koerkamp B, [van der Geest LG](#), de Hingh IH, van Santvoort HC, Besselink MG, Gerhards MF; Dutch Pancreatic Cancer Group. Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes. *BJS Open*. 2020 Aug 25. doi: 10.1002/bjs5.50319.

## 12 Urogenitale kanker

### 12.1 Publicaties met impactfactor

Evers J, Grotenhuis AJ, **Aben KK**, Kiemeney LA, Vrieling A. No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. *PLoS One*. 2020 Mar 25;15(3):e0229384. doi: 10.1371/journal.pone.0229384. eCollection 2020. Impactfactor: 2,740

Freund JE, Duivenvoorden MJ, Sikma BT, **Vernooij RW**, Savci-Heijink CD, Legemate JD, de Reijke TM. The diagnostic yield and concordance of ureterorenoscopic biopsies for grading of upper tract urothelial carcinoma: a Dutch nationwide analysis. *J Endourol*. 2020 Sep;34(9):907-913. doi: 10.1089/end.2020.0246. Epub 2020 Jul 16. Impactfactor: 2,328

Jahreis MC, **Aben KK**, Hoogeman MS, Dirx ML, de Vries KC, Incrocci L, Heemsbergen WD. The risk of second primary cancers in prostate cancer survivors treated in the modern radiotherapy era. *Front Oncol*. 2020 Nov 13;10:605119. doi: 10.3389/fonc.2020.605119. eCollection 2020. Impactfactor: 4,848

Kuppen MC, Westgeest HM, van der Doelen MJ, van den Eertwegh AJ, Coenen JL, **Aben KK**, van den Bergh AC, Bergman AM, den Bosch JV, Celik F, Hendriks MP, Lavalaye J, der Meer SV, Polee MB, Somford DM, van Oort IM, Uyl-de Groot CA, Gerritsen WR. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. *Future Oncol*. 2020 May 29. doi: 10.2217/fon-2020-0039. Online ahead of print. Impactfactor: 2,660

Nakata K, Colombet M, Stiller CA, Pritchard-Jones K, Steliarova-Foucher E, IICC-3 contributors (**Visser O**). Incidence of childhood renal tumours: an international population-based study. *Int J Cancer*, published online 16 June 2020. <https://doi.org/10.1002/ijc.33147>. Impactfactor: 5,145

Notohardjo JC, Kuppen MC, Westgeest HM, van Moorselaar RJ, Mehra N, Coenen JL, van Oort IM, de Vos AI, Vervenne WL, van den Bergh AC, **Aben KK**, Somford DM, Bergman AM, Uyl-de Groot CA, Gerritsen WR, van den Eertwegh AJ. Third-line life-prolonging drug treatment in a real-world metastatic castration-resistant prostate cancer population: results from the Dutch Castration-resistant Prostate Cancer Registry. *Eur Urol Focus*. 2020 Apr 30. pii: S2405-4569(20)30097-3. doi: 10.1016/j.euf.2020.03.009. [Epub ahead of print] Impactfactor: 4,827

**Ripping TM**, Witjes JA, Meijer RP, van Rhijn BW, Oddens JR, Goossens-Laan CA, Mulder SF, van Moorselaar RJ, Kiemeney LA, **Aben KK**. Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. *Urol Oncol*. 2020 Sep 8:S1078-1439(20)30381-1. doi: 10.1016/j.urolonc.2020.08.014. Online ahead of print. Impactfactor: 2,882

**Ripping TM**, Kiemeney LA, **van Hoogstraten LM**, Witjes JA, **Aben KK**; BlaZIB study group. BMC. Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB). *Cancer*. 2020 May 20;20(1):455. doi: 10.1186/s12885-020-06954-7. Impactfactor: 5,772

van Doeveren T, van de Werken HJ, van Riet J, **Aben KK**, van Leeuwen PJ, Zwarthoff EC, Boormans JL. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review. *Urol Oncol*. 2020 Feb 11. pii: S1078-1439(20)30009-0. doi: 10.1016/j.urolonc.2020.01.008. [Epub ahead of print] Review. Impactfactor: 2,882

**van Santvoort BW**, van Leenders GJ, Kiemeneij LA, van Oort IM, **Wieringa SE**, **Jansen H**, **Vernooij RW**, Hulsbergen-van de Kaa CA, **Aben KK**. Histopathological re-evaluations of biopsies in prostate cancer: a nationwide observational study. *Scand J Urol*. 2020 Aug 26:1-7. doi: 10.1080/21681805.2020.1806354. Online ahead of print. Impactfactor: 1,362

**Vernooij RW**, **Lancee M**, Cleves A, Dahm P, Bangma CH, **Aben KK**. Radical prostatectomy versus deferred treatment for localised prostate cancer. *Cochrane Database Syst Rev*. 2020 Jun 4;6(6):CD006590. doi: 10.1002/14651858.CD006590.pub3. Impactfactor: 7,890

**Vernooij RW**, Cremers RG, **Jansen H**, Somford DM, Kiemeneij LA, van Andel G, Wijsman BP, Busstra MB, van Moorselaar RJ, **Wijnen EM**, Pos FJ, Hulshof MC, Hamberg P, van den Berkmoortel F, Hulsbergen-van de Kaa CA, van Leenders GJ, Fütterer JJ, van Oort IM, **Aben KK**. Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: a nationwide observational study. *Urol Oncol*. 2020 Jul 15:S1078-1439(20)30251-9. doi: 10.1016/j.urolonc.2020.05.022. Online ahead of print. Impactfactor: 2,882

Wollersheim BM, van Asselt KM, van der Poel HG, van Weert HC, Hauptmann M, Retèl VP, Aaronson NK, **van de Poll-Franse LV**, Boekhout AH. Design of the PROstate cancer follow-up care in Secondary and Primary hEalth Care study (PROSPEC): a randomized controlled trial to evaluate the effectiveness of primary care-based follow-up of localized prostate cancer survivors. *BMC Cancer*. 2020 Jul 8;20(1):635. doi: 10.1186/s12885-020-07112-9. Impactfactor: 3,15

## 12.2 Overige publicaties

**Lemmens VE**, van Aubel OG. High-intensity focussed ultrasound (HIFU) als salvagebehandeling van recidiverend prostaatcarcinoom: stand van zaken wetenschap en praktijk: een review van systematische reviews. *Tijdschr Urol*. 2020 May doi:10.1007/s13629-020-00291-x.

**Richters A**, Mehra N, Meijer RP, Boormans JL, van der Heijden AG, Smilde TJ, van der Heijden MS, Kiemeneij LA, **Aben KK**. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. *Cancer Treat Res Commun*. 2020 Dec 8;25:100266. doi: 10.1016/j.ctarc.2020.100266. Online ahead of print.

Steenhaar RV, Kremers MN, Michon LA, **Zijlstra M**, Haak HR. Patient and Partner Perspectives on Health-Related Quality of Life in Adrenocortical Carcinoma. *J Endocr Soc*. 2020 Apr 1;4(5):bvaa040. doi: 10.1210/endo/bvaa040. eCollection 2020 May 1.

## B1 Impactfactoren tijdschriften

In 2020 zijn er 238 artikelen gepubliceerd in 127 peer-reviewed journals waarvan 109 met een impactfactor. De hoogste impactfactor was 33,752 (The Lancet Oncology) en de gemiddelde impactfactor bedroeg 5,6 (© 2019 Journal Citation Report © Clarivate Analytics, 2020).

**Tabel 1** Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Acta Dermato-Venerologica	4,016	1
Acta Obstetrica et Gynecologica Scandinavica	2,770	1
Acta Oncologica	3,701	11
AJHG American Journal of Human Genetics	10,502	1
AJOG American Journal of Obstetrics and Gynecology	6,502	1
Anais Brasileiros de Dermatologica	1,121	1
Annals of Hematology	2,904	1
Annals of Oncology	18,274	2
Annals of Surgical Oncology	4,061	7
Annals of Surgery	10,13	1
Anticancer Research	1,994	1
BJC British Journal of Cancer	5,791	5
BJD British Journal of Dermatology	7,0	1
BJH British Journal of Haematology	5,518	3
BJN British Journal of Nutrition	3,334	1
BJS British Journal of Surgery	5,676	2
Blood Advances	4,910	1
BMC Cancer	3,15	3
BMC Medical Informatics and Decision Making	2,317	2
BMC Palliative Care	2,015	1
BMJ British Medical Journal	30,313	1
BMJ Open	2,496	1
BMJ Supportive & Palliative Care	2,681	1
Breast Cancer Research and Treatment	3,831	10
British Journal of General Practice	4,190	1
Cancer	5,772	4
Cancer Epidemiology	2,179	2
Cancer Epidemiology, Biomarkers & Prevention	4,344	2
Cancer Medicine	3,491	3
Cancers (Basel)	6,126	5
Cells	4,829	1
Clinical and Translational Medicine	7,919	1
Clinical Gastroenterology and Hepatology	8,549	2
Clinical Lung Cancer	3,550	1
Clinical Nutrition ESPEN	6,360	1
Clinical Oncology	3,113	1
Cochrane Database of Systematic Reviews	7,890	1
Critical Reviews in Oncology/Hematology	5,833	1
Current Oncology Reports	3,828	1

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
EJC European Journal of Cancer	7,275	7
EJSO European Journal of Surgical Oncology	3,959	7
ESMO Open cancer horizons	5,329	1
European Archives of Oto-Rhino-Laryngology	1,809	1
European Journal of Cancer Care (Engl.)	2,161	1
European Journal of Health Economics	2,367	1
European Journal of Nuclear Medicine and Molecular Imaging	7,081	1
European Journal of Oncology Nursing	1,876	1
European Respiratory Journal	12,339	1
European Urology Focus	4,827	1
Frontiers in Oncology	4,848	1
Future Oncology	2,660	1
Gastric Cancer	7,088	1
GIE Gastrointestinal Endoscopy	6,890	1
Gynecologic Oncology	4,623	2
Haematologica	7,116	1
Head & Neck	2,538	1
Health and Quality of Life Outcomes	2,344	1
HPB	3,401	1
IJC International Journal of Cancer	5,145	5
International Journal for Quality in Health Care	1,957	1
International Journal of Colorectal Disease	2,108	1
International Journal of Gynecological cancer	2,095	1
International Journal of Oral & Maxillofacial Surgery	2,068	2
International Journal of Radiation Oncology Biology Physics	5,859	1
JAMA Dermatology	7,738	2
JAMA Oncology	24,799	2
JMIR Journal of Medical Internet Research	5,034	2
JNCI Journal of the National Cancer Institute	11,577	1
JPD Journal of Prosthetic Dentistry	2,444	1
Journal of Adolescent and Young Adult Oncology (JAYAO)	1,599	1
Journal of Cancer Survivorship	3,296	6
Journal of Clinical Oncology	32,956	1
Journal of Endourology	2,328	1
Journal of Geriatric Oncology	2,761	1
Journal of Gynecologic Oncology	3,304	1
Journal of Hematology & Oncology	11,059	2
Journal of Molecular Diagnostics	5,553	1
Journal of Oral Pathology & Medicine	2,495	1
Journal of the national comprehensive cancer network	9,316	3
Journal of Thoracic Oncology	13,357	1
Journal of Urology	5,925	1
Leukemia	8,665	6
Leukemia & lymphoma	2,969	2
Lung Cancer	4,702	2
Nature Genetics	27,605	1
Neuroendocrinology	4,271	2



<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
NPJ Breast Cancer	6,0	1
Palliative medicine	3,739	1
Pancreatology	3,629	1
Pediatric Anesthesia	2,311	1
Plastic and Reconstructive Surgery	4,235	1
Plos One	2,740	5
Psycho-Oncology	3,006	1
Psychology & Health	2,528	1
Quality of Life Research	2,773	1
Radiology	7,931	2
Radiotherapy and Oncology	4,856	2
Scandinavian Journal of Urology	1,362	1
Scientific Reports	3,998	2
Supportive Care in Cancer	2,635	7
Surgical Oncology	2,521	1
Systematic reviews	2,479	1
The Lancet Oncology	33,752	2
The Oncologist	5,025	2
Therapeutic advances in gastroenterology	3,520	1
Trials	1,883	3
UEG United European Gastroenterology Journal	3,549	1
Urologic Oncology: Seminars and Original Investigations	2,882	3
Value in Health	4,748	4

**Tabel 2** Overzicht tijdschriften zonder impactfactor

Asia-Pacific Journal of Oncology Nursing	1
BJGP Open	1
BJS Open	1
Cancer Treatment and Research Communications	1
HemaSphere	1
JCO Clinical Cancer Informatics	2
JCO Global Oncology	1
JES Journal of the Endocrine Society	1
JNCI cancer spectrum	1
Journal of cancer policy	1
Melanoma Management	2
Neuro-Oncology Advances	1
NtvG Nederlands Tijdschrift voor Geneeskunde	2
NTvT Nederlands Tijdschrift voor Tandheelkunde	1
Sarcoma	2
Studies in Health Technology and Informatics	1
TSG Tijdschrift voor Gezondheidswetenschappen	1
Tijdschrift voor Urologie	1

Integraal Kankercentrum  
Nederland  
info@iknl.nl  
www.iknl.nl

